<SEC-DOCUMENT>0001213900-26-086149.txt : 20260806
<SEC-HEADER>0001213900-26-086149.hdr.sgml : 20260806
<ACCEPTANCE-DATETIME>20260806161150
ACCESSION NUMBER:		0001213900-26-086149
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20260806
DATE AS OF CHANGE:		20260806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OS Therapies Inc
		CENTRAL INDEX KEY:			0001795091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				825118368
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-289443
		FILM NUMBER:		261249148

	BUSINESS ADDRESS:	
		STREET 1:		15825 SHADY GROVE ROAD
		STREET 2:		SUITE 135
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		410-297-7793

	MAIL ADDRESS:	
		STREET 1:		15825 SHADY GROVE ROAD
		STREET 2:		SUITE 135
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OS THERAPIES Inc
		DATE OF NAME CHANGE:	20191125
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>ea0297531-424b5_ostherapies.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Prospectus Supplement</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed Pursuant to Rule 424(b)(5)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(To Prospectus dated August 25, 2025)</B></FONT></TD>
    <TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration No. 333-289443</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>500,000 Shares</B>&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea029753101_img1.jpg" ALT="" STYLE="width: 400px; height: 64px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OS THERAPIES INCORPORATED<BR>
Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to this prospectus
supplement and the accompanying prospectus, we are offering 500,000 shares of our common stock to Leonite Fund I, LP (&ldquo;Leonite&rdquo;),
as part of the consideration for the transactions contemplated by the settlement agreement and mutual release, dated as of July
31, 2026, between us, our wholly owned subsidiaries and Leonite (the &ldquo;Leonite Settlement Agreement&rdquo;). See &ldquo;Prospectus
Supplement Summary&mdash;Recent Developments&mdash;Leonite Settlement&rdquo; for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is traded
on the NYSE American under the symbol &ldquo;OSTX.&rdquo; On August 5, 2026, the closing price of our common stock on the NYSE American
was $1.60 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common stock
are being offered directly to Leonite without the use of any placement agent, underwriter or broker-dealer. We are not paying any underwriting
discounts or commissions in connection with this offering. We will not receive any cash proceeds from the sale of the shares of our common
stock in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &ldquo;emerging
growth company&rdquo; and a &ldquo;smaller reporting company&rdquo; under U.S. federal securities laws, and as such, we have elected to
comply with certain reduced public company reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our common
stock involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page S-6 of this prospectus supplement and page 3 of
the accompanying base prospectus, as well as the information under the heading &ldquo;Risk Factors&rdquo; in our Annual Report on Form
10-K for the year ended December 31, 2025, and in the other documents incorporated by reference into this prospectus supplement and the
accompanying base prospectus for a discussion of the factors you should carefully consider before investing in our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
supplement or the accompanying base prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Delivery of the shares of
common stock in this offering is expected to be made on or about August 6, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Prospectus Supplement dated August 6, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus Supplement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 92%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#s_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">About This Prospectus Supplement</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">S-ii</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#s_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Special Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">S-iii</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#s_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Prospectus Supplement Summary</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">S-1</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#s_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">The Offering</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">S-5</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#s_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Risk Factors</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">S-6</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#s_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Use of Proceeds</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">S-7</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#s_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Dividend Policy</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">S-7</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#s_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Dilution</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">S-8</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#s_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Plan of Distribution</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">S-9</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#s_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Legal Matters</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">S-10</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#s_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Experts</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">S-10</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#s_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">S-10</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#s_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Incorporation of Certain Information by Reference</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">S-11</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 92%">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">About This Prospectus</FONT></A></TD>
    <TD STYLE="text-align: center">ii</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ABOUT THE COMPANY</FONT></A></TD>
    <TD STYLE="text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">CAUTIONARY STATEMENT Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">USE Of proceeds</FONT></A></TD>
    <TD STYLE="text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">dESCRIPTION OF OUR cAPITAL sTOCK</FONT></A></TD>
    <TD STYLE="text-align: center">6</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">dESCRIPTION OF oUR dEBT sECURITIES</FONT></A></TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DESCRIPTION OF OUR WARRANTS</FONT></A></TD>
    <TD STYLE="text-align: center">18</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DESCRIPTION OF OUR RIGHTS</FONT></A></TD>
    <TD STYLE="text-align: center">22</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Description of OUR UNITS</FONT></A></TD>
    <TD STYLE="text-align: center">23</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: center">24</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">SELLING STOCKHOLDERS</FONT></A></TD>
    <TD STYLE="text-align: center">29</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: center">30</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: center">30</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: center">30</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: center">31</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_001"></A>ABOUT THIS PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement
and the accompanying prospectus are part of a registration statement on Form&nbsp;S-3&nbsp;that we filed with the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;), using a &ldquo;shelf&rdquo; registration process. Under this shelf registration process, we may from
time to time sell any combination of the securities described in the accompanying prospectus in one or more offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This document is in two parts.
The first part, including the documents incorporated herein by reference, is the prospectus supplement, which describes the specific terms
of this offering. The second part, including the documents incorporated therein by reference, is the accompanying prospectus, which provides
more general information. Generally, when we refer to &ldquo;this prospectus,&rdquo; we are referring to both parts of this document combined.
We urge you to carefully read this prospectus supplement, the accompanying prospectus and the documents incorporated by reference into
this prospectus supplement and the accompanying prospectus, before buying any of our common stock being offered under this prospectus
supplement. This prospectus supplement may add, update or change information contained in the accompanying prospectus. If the information
varies between this prospectus supplement and the accompanying prospectus, you should rely on the information contained in this prospectus
supplement; provided that if any statement in one of these documents is inconsistent with a statement in another document having a later
date &mdash; for example, a document incorporated by reference in the accompanying prospectus &mdash; the statement in the document having
the later date modifies or supersedes the earlier statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not authorized anyone
to provide you with any information or to make any representation, other than those contained or incorporated by reference in this prospectus
supplement and the accompanying prospectus, or in any free writing prospectus prepared by us or on our behalf or to which we have referred
you. We do not take any responsibility for, and provide no assurance as to the reliability of, any other information that others may give
you. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated
by reference in this prospectus supplement and the accompanying prospectus and any free writing prospectus is accurate only as of the
respective dates of those documents. Our business, financial condition, results of operations and prospects may have changed since those
dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We further note that the representations,
warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in
the prospectus supplement or the accompanying base prospectus were made solely for the benefit of the parties to such agreement, including,
in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly,
such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are offering to sell, and
seeking offers to buy, our common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus
supplement and the offering of our common stock in certain jurisdictions may be restricted by law. Persons outside the United States who
come into possession of this prospectus supplement must inform themselves about, and observe any restrictions relating to, the offering
of our common stock and the distribution of this prospectus supplement outside the United States. This prospectus supplement does not
constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any common stock offered by
this prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The industry and market data
and certain other statistical information used throughout this prospectus supplement, the accompanying base prospectus and the documents
incorporated by reference into the prospectus and this prospectus supplement are from our own research, surveys or studies conducted by
third parties and industry or general publications. Industry publications and third-party research, surveys and studies generally indicate
that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness
of such information. We are responsible for all of the disclosures contained in this prospectus supplement, the accompanying base prospectus
and the documents incorporated by reference into the prospectus and this prospectus supplement, and we believe that these sources are
reliable; however, we have not independently verified the information contained in such publications. While we are not aware of any misstatements
regarding any third-party information presented in this prospectus supplement, their estimates, in particular, as they relate to projections,
involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those
discussed under the section entitled &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus supplement, the accompanying base prospectus
and the documents incorporated by reference into the prospectus and this prospectus supplement. Some data are also based on our good faith
estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">SiLinkers&trade;,
CAPs&trade; and other common law trade names, trademarks or service marks of our company appearing in this prospectus supplement, the
accompanying base prospectus and the documents incorporated by reference into the prospectus and this prospectus supplement are our property.
This prospectus supplement, the accompanying base prospectus and the documents incorporated by reference into the prospectus and this
prospectus supplement contain additional trade names, trademarks and service marks of other companies that are owned by their respective
owners. Solely for convenience, trademarks and trade names referred to in this prospectus supplement, the accompanying base prospectus
and the documents incorporated by reference into the prospectus and this prospectus supplement appear without the &trade; or &reg; symbols,
but such an omission is not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that
the applicable owners will not assert their rights, to these trademarks and trade names. We do not intend our use or display of other
companies&rsquo; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship by us of, these
other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this prospectus
supplement and the accompanying base prospectus to &ldquo;OS Therapies,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo;
&ldquo;our&rdquo; or similar references refer to OS Therapies Incorporated, except where the context otherwise requires or as otherwise
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_002"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
prospectus supplement, the accompanying base prospectus and the documents incorporated by reference in these documents contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and Section
21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), which may include information concerning our
beliefs, plans, objectives, goals, expectations, strategies, anticipations, assumptions, estimates, intentions, future events, future
revenues or performance, capital expenditures and other information that is not historical information. Forward-looking statements involve
known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance
or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking
statements. When used in this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference in these
documents, the words &ldquo;seek,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;project,&rdquo;
&ldquo;plan,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;plan,&rdquo; &ldquo;continue,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe&rdquo;
and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements
are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs,
but there can be no assurance that we will realize our expectations or that our beliefs will prove to be correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
are a number of risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements contained
in this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference in these documents. Examples
of risks and uncertainties that could cause actual results to differ materially from historical performance and any forward-looking statements
include, but are not limited to, the risks described under the section below titled &ldquo;Risk Factors&rdquo; of this prospectus supplement,
as well as any of our subsequent filings with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
may be other factors of which we are currently unaware or which we currently deem immaterial that may cause our actual results to differ
materially from the forward-looking statements. All forward-looking statements attributable to us or persons acting on our behalf apply
only as of the date they are made and are expressly qualified in their entirety by the cautionary statements included in this prospectus
supplement, the accompanying base prospectus and the documents incorporated by reference in these documents. Except as may be required
by federal securities law, we undertake no obligation to publicly update or revise any forward-looking statement to reflect events or
circumstances occurring after the date they were made or to reflect the occurrence of unanticipated events, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_003"></A>PROSPECTUS SUPPLEMENT SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights
selected information about us and this offering and does not contain all of the information that you should consider in making your investment
decision. You should carefully read this entire prospectus supplement and the accompanying prospectus, including the risks and uncertainties
discussed under the heading &ldquo;Risk Factors&rdquo; beginning on page S-6 of this prospectus supplement, and the information incorporated
by reference in this prospectus supplement and the accompanying prospectus, including our consolidated financial statements and related
notes, before making an investment decision. If you invest in our common stock, you are assuming a high degree of risk.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OS Therapies is a clinical
stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and
other solid tumors. Our mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to its location, changing
genotypes and high metastases rates. We are currently seeking to answer the call for new treatments that will prevent metastasis and the
recurrence of metastases with our lead core product candidate OST-HER2 (also known as OST31-164), a cancer immunotherapy product candidate
that produces a cellular immune response against the cancer antigen HER2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2021, we opened a clinical
study to produce data for the U.S. Food and Drug Administration (FDA) to evaluate the safety and efficacy of OST-HER2 in patients after
resection of recurrent Osteosarcoma, which achieved full enrollment of 41 patients in October 2023. In the first quarter of 2025, we announced
that our Phase IIb clinical trial achieved its primary endpoint with statistical significance. In October 2025, we announced final two-year
overall survival data from the Phase IIb trial, in which 75% (27 of 36 evaluable patients) of OST-HER2-treated patients achieved two-year
overall survival from the most recent pulmonary resection, compared with 60% in historical control patients (p = 0.034). OST-HER2 was
observed to be well-tolerated in the study. In January 2026, we announced positive immune biomarker data from the Phase IIb trial indicating
that activation of immune blood biomarkers in the interferon gamma pathway correlated with, and was predictive of, overall survival, distinguishing
long-term survivors (&ge; two years) from short-term survivors (&lt; one year). These biomarker findings are based on exploratory analyses
and have not been validated as surrogate endpoints for clinical benefit. In May 2026, we announced that the Phase IIb trial demonstrated
a statistically significant overall survival benefit at the 2.5-year timepoint, with 75% overall survival in OST-HER2-treated patients
compared with 47% in pooled historical control patients (p = 0.003). No new patient deaths were reported in the OST-HER2-treated group
between the two-year and 2.5-year analyses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have engaged in ongoing
regulatory interactions with the FDA, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA), and the European
Medicines Agency (EMA) regarding the clinical and biomarker data for OST-HER2 in recurrent, fully resected pulmonary metastatic Osteosarcoma.
We anticipate submitting the clinical Biologics License Application (BLA) module following an expected Type B meeting with the FDA in
the second half of 2026 and completing conditional Marketing Authorization Application (MAA) submissions to both the MHRA and the EMA
in the second half of 2026. We expect to initiate confirmatory clinical studies in the second half of 2026 in support of conditional approval
pathways. We expect to receive three-year overall survival data in the third quarter of 2026. If OST-HER2 receives approval under the
FDA&rsquo;s Accelerated Approval Program prior to September 30, 2029, we would become eligible to receive a Priority Review Voucher under
the Rare Pediatric Disease Designation Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon success in gaining regulatory
approval from the FDA with OST-HER2 in Osteosarcoma, we intend to evaluate OST-HER2&rsquo;s potential use, both alone and in combination
with HER2 targeting antibodies such as Herceptin&reg;, in other solid tumors including breast, esophageal and lung cancers. OST-HER2 has
potential uses in both the prevention of metastases in solid tumors, and therapeutically against HER2-expressing solid tumors treated
with HER targeting antibodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also own rights to an OST-Tunable
Drug Conjugate (OST-tADC) platform, a next generation antibody-drug conjugate (ADC) silicone dioxide linker technology. &ldquo;Tunable&rdquo;
is a term used in drug development that refers to the properties that can be influenced by chemical modifications, and &ldquo;antibody-drug
conjugate&rdquo; or ADC is a term used to describe a drug made up of a monoclonal antibody attached to a cytotoxic payload, or a highly
active and toxic pharmaceutical molecule, through chemical linkers. The ADC links an antibody that can home in on a targeted tumor to
deploy the cytotoxic payload or toxic agent against the tumor. Furthering our founding mission, we intend to investigate clinical indications
for OST-tADC in Osteosarcoma and other solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have built a pipeline of
product candidates targeting multiple indications for solid cancers. Our pipeline includes two drug technologies: (i)&nbsp;OST-HER2, an
off-the-shelf immunotherapy, which is a type of cancer treatment that helps one&rsquo;s immune system fight cancer, comprised of a genetically
weakened and modified strain of <I>Listeria monocytogenes</I>, a species of bacteria that causes the infection listeriosis, that expresses
HER2 peptides, and (ii)&nbsp;OST-tADC,&nbsp;a next generation tunable ADC with a plug-and-play platform that features tunable pH sensitive
silicone linkers (SiLinkers&trade;). The payloads may include antibodies, chemotherapeutics, cytotoxins and potentially mRNA treatments
directly into and in the vicinity of solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>OST-HER2 (OST31-164).
</I></B>Our most advanced product candidate, OST-HER2, is a genetically engineered strain of <I>Listeria monocytogenes</I>, attenuated
for reduced virulence, increased antibiotic susceptibility and the expression of three HER2 protein epitopes fused to immune-enhancing
peptides on the membrane of the bacteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OST-HER2 has received an orphan
drug designation in the United&nbsp;States. The FDA may designate a biologic product as an orphan product if it is intended to treat a
rare disease or condition, which generally is defined as having a patient population of fewer than 200,000 individuals in the United&nbsp;States.
Osteosarcoma has an incidence rate of approximately 1,000 individuals affected per year in the United&nbsp;States. Orphan product designation,
subject to limited exceptions, can provide a period of market exclusivity for a product that is the first to receive marketing approval
for the designated indication. Other potential indications may include breast, esophageal, lung and other solid tumors. In August&nbsp;2021,
OST-HER2 was awarded rare pediatric disease designation and previously received fast track designation by the FDA.&nbsp;Such designations
by the FDA do not convey any advantages in, or shorten the duration of, the regulatory review or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>OST-tADC. </I></B>Our
tunable drug conjugate (tADC) platform is currently in preclinical development. Each tADC contains four main components: ligand, payload
cassette adaptor, linker and payload. In addition, tADCs contain units to optimize physicochemical properties. The ligands are selected
to bind to receptors overexpressed on cancer cells. Upon binding, the tADC construct gets internalized into the cancer cell, where the
payload is released, to cause cell death. The payload cassette adaptors enable the stoichiometrical attachments of linkers and payloads.
The SiLinkers represent a novel and pH-sensitive linker system. The SiLinker release profile can be tuned with proximal functional groups,
resulting in payload release in the endosome, lysosome or the slightly acidic tumor microenvironment. The SiLinker system is compatible
with a variety of payloads and not limited to the employment of cytotoxic drug delivery. The first set of internal programs focus on the
use of SiLinker and conditionally active payloads (CAPs&trade;) drug products. CAPs are cytotoxic drugs which on their own, due to their
functional groups, cannot readily permeate cells at physiological pH; however, at the slightly acidic pH of the tumor-microenvironment,
after some linker cleavage, these payloads readily permeate into cancer cells, resulting in an enhanced bystander effect. Our lead program
targets folate receptor alpha, a protein expressed on the surface of cells that participates in cell signaling, as well as cellular replication
and division, and is overexpressed in multiple cancers such as ovarian and endometrial cancers. The lead compound employs folic acid,
a small molecule, as the targeting ligands and contains six exatecan-silanols, which is a type of silanol-based cytotoxic payload. This
discovery work is being carried out at Syngene International Limited, an integrated contract research organization (CRO) based in Bangalore,
India.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
evaluate collaboration opportunities for our product candidates. We expect to work opportunistically with pharmaceutical and biotechnology
companies, as we have done with BlinkBio, Inc. by in-licensing the OST-tADC technology, seeking to utilize our technology and know-how
for developing additional oncologic drug products. The following table summarizes information regarding our product candidates and development
programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea029753101_img2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea029753101_img3.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to our development
of OST-HER2 for multiple indications of solid cancers in humans, OST-HER2 is a product candidate for veterinary use in canines. As part
of our growth strategies, we intend to consider potentially out-licensing OST-HER2 to animal health companies for such use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>2026 Registered Direct Offering</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 2, 2026, we completed
a registered direct offering, pursuant to which we offered and sold to accredited investors an aggregate of 2,505,073 shares of our common
stock and, in lieu thereof, pre-funded warrants to purchase up to 1,250,893 shares of our common stock, and accompanying common warrants
to purchase up to 3,755,966 shares of our common stock (the &ldquo;2026 Registered Direct Offering&rdquo;). The combined purchase price
for each share and common warrant in the 2026 Registered Direct Offering was $1.40, and the purchase price for each pre-funded warrant
and common warrant in the 2026 Registered Direct Offering was $1.399, which was equal to the per share and common warrant purchase price,
minus $0.001. We received net&nbsp;proceeds from the 2026 Registered Direct Offering of approximately $4.7 million. We are using the net
proceeds to fund clinical development activities, including ongoing and planned clinical trials, advance our research and development
programs, as well as for working capital and other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon consummation of the 2026
Registered Direct Offering, the 10.0% original issue discount unsecured convertible promissory notes in an aggregate principal amount
of $2,200,000 issued in connection with our bridge financing in March 2026, together with all accrued and unpaid interest thereon, automatically
converted into an aggregate of 1,576,311 shares of our common stock and warrants to purchase up to 1,576,311 shares of our common stock
(the &ldquo;Bridge Conversions&rdquo;). The warrants were issued on the same terms as the common warrants issued in the 2026 Registered
Direct Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the 2026
Registered Direct Offering, Ceros Financial Services, Inc. (&ldquo;Ceros&rdquo;) acted as our exclusive placement agent. We paid Ceros
a cash fee equal to 7.0% of the gross proceeds raised in the 2026 Registered Direct Offering. We also reimbursed Ceros up to $70,000 for
its reasonable and documented out-of-pocket accountable expenses and up to $20,000 for its non-accountable expenses. We also issued to
Ceros&rsquo;s designees warrants to purchase up to an aggregate of 187,798 shares of our common stock. The placement agent warrants have
an exercise price of $1.54 per share, are exercisable beginning September 2, 2026 and expire five years from April 2, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Termination of Prior Sales Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2025, we entered
into an at market issuance sales agreement with B. Riley Securities, Inc. and JonesTrading Institutional Services LLC (the &ldquo;Prior
Sales Agreement&rdquo;), pursuant to which we could offer and sell shares of our common stock having an aggregate offering price of up
to $18,000,000. Effective as of July 28, 2026, we terminated the Prior Sales Agreement. At the time of termination, we had sold an aggregate
of 282,679 shares of our common stock for aggregate gross proceeds of approximately $530,162 under the Prior Sales Agreement and the related
prospectus supplement dated August 25, 2025 (the &ldquo;Prior Prospectus Supplement&rdquo;), and approximately $17,469,838 remained unsold
thereunder. No further shares of our common stock may or will be offered or sold under the Prior Sales Agreement or the Prior Prospectus
Supplement. The unsold amount under the Prior Prospectus Supplement will remain available for sale in other offerings pursuant to the
accompanying base prospectus and a corresponding prospectus supplement, subject to applicable law, any applicable limitations under Form
S-3 and the continued effectiveness of the registration statement of which this prospectus supplement and the accompanying prospectus
form a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>2026 Secured Financing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 30, 2026, we, together
with our wholly owned subsidiaries, entered into a securities purchase agreement (the &ldquo;Leonite SPA&rdquo;) with Leonite and related
transaction documents, pursuant to which we issued and sold to Leonite, in a private placement (the &ldquo;Leonite Private Placement&rdquo;),
a senior secured convertible promissory note in an aggregate principal amount of up to $10,000,000 (the &ldquo;Leonite Note&rdquo;). As
additional consideration for Leonite&rsquo;s purchase of the Leonite Note, we issued to Leonite (i) 275,000 shares of our common stock
(the &ldquo;Leonite Commitment Shares&rdquo;) and (ii) a five-year warrant to purchase up to 1,750,000 shares of our common stock (the
&ldquo;Leonite Warrant&rdquo;) at an initial exercise price of $2.85 per share, subject to adjustment as provided therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Leonite SPA,
Leonite agreed to purchase the Leonite Note in one or more tranches, in an aggregate principal amount of up to $10,000,000. Each funded
tranche was subject to an original issue discount of 7.5%, which was included in the principal amount of the Leonite Note and was earned
only upon the funding of such tranche. On July 2, 2026, Leonite funded the initial tranche in the principal amount of $1,600,000 (less
$35,000 retained by Leonite for legal fees and expenses).</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Leonite Note was secured
by a continuing first-priority security interest in substantially all of our and our subsidiaries&rsquo; existing and after-acquired assets,
subject to certain exclusions, including intellectual property assets. Notwithstanding such exclusions, the collateral included accounts,
payment intangibles and other rights to payment arising from the sale, license or other disposition of intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Leonite Settlement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 31, 2026, we, together
with our wholly owned subsidiaries, entered into the Leonite Settlement Agreement, pursuant to which we agreed to pay Leonite $1,900,000
in cash (the &ldquo;Settlement Payment&rdquo;) and issue to Leonite 500,000 shares of our common stock (the &ldquo;Settlement Shares&rdquo;)
on or before August 7, 2026 (the &ldquo;Outside Date&rdquo;) in full and complete satisfaction of all amounts outstanding under the Leonite
Note and the other transaction documents related to the Leonite Private Placement (the &ldquo;Leonite Settlement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 2, 2026, in connection
with the Leonite Settlement, we issued to an accredited investor a bridge convertible promissory note in the principal amount of $2,200,000
(the &ldquo;Bridge Note&rdquo;) for a purchase price of $2,190,000 (the &ldquo;August Bridge Financing&rdquo;). The Bridge Note does not
bear interest and matures on September 1, 2026, unless earlier converted by the holder. We may not prepay the Bridge Note without the
prior written consent of the holder. Upon the initial closing of a private offering by us of original issue discount promissory notes
in an aggregate principal amount of up to $10,000,000, the outstanding principal amount of the Bridge Note will automatically convert
into the securities issued in such offering on the same terms as the other purchasers in the offering. The Bridge Note also contains customary
events of default, upon the occurrence of which the holder may declare the outstanding principal amount of the Bridge Note to be immediately
due and payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 3, 2026, in accordance
with the terms of the Bridge Note, we used the proceeds from the August Bridge Financing to fund the Settlement Payment. We are required
to issue the Settlement Shares on or before the Outside Date. We are registering the Settlement Shares pursuant to this prospectus supplement
and the accompanying base prospectus, and we expect to issue the Settlement Shares to Leonite on or about August 6, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective upon the closing
of the Leonite Settlement, which will occur upon Leonite&rsquo;s receipt of both the Settlement Payment (which was paid on August 3, 2026)
and the Settlement Shares offered hereby: (i) the Leonite Note and all amounts outstanding thereunder will be deemed fully paid, satisfied,
discharged and cancelled, and all conversion rights thereunder will terminate; (ii) the Leonite Warrant will be terminated and cancelled
in its entirety, unexercised; (iii) the Leonite Commitment Shares will be surrendered by Leonite to us for cancellation; (iv) the Leonite
SPA, the related security agreement and all other transaction documents entered into in connection with the Leonite Private Placement
will terminate and cease to be of any further force or effect, including all rights of Leonite under the participation rights, rights
of first refusal, future financing rights, disclosure rights relating to future financings, rollover rights and registration rights provisions
of the Leonite SPA; and (v) all security interests, liens, pledges and other collateral granted to or for the benefit of Leonite will
be automatically, unconditionally and irrevocably released, terminated and discharged, and all assets assigned to Leonite by OS Therapies
UK Ltd, our wholly owned subsidiary (&ldquo;OSUK&rdquo;), including value added tax repayments and research and development tax relief
claims, will revert to OSUK free and clear of any claim or lien of Leonite.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, effective upon
the closing of the Leonite Settlement, the parties agreed to exchange unconditional mutual releases of all claims, counterclaims, demands,
actions and causes of action of every kind and nature, whether known or unknown, suspected or unsuspected, arising out of, relating to
or in connection with any act, omission, event or occurrence existing at or prior to the closing, including the transaction documents
entered into in connection with the Leonite Private Placement, the transactions contemplated thereby and the disputes between the parties,
subject to a customary carve-out preserving the parties&rsquo; respective rights and obligations under the Leonite Settlement Agreement.
Each party also agreed to waive, to the fullest extent permitted by law, the provisions, rights and benefits of any statute, rule, doctrine
or common law principle that would limit the scope or effectiveness of a general release with respect to unknown or unsuspected claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the closing of the Leonite
Settlement does not occur on or before the Outside Date (other than due to Leonite&rsquo;s willful refusal to accept a proper tender),
we have a five-business day cure period. If the closing has no occurred by the end of the cure period, Leonite will have the right to
terminate the Leonite Settlement Agreement, in which case the Leonite Note, the Leonite Warrant and all other transaction documents entered
into in connection with the Leonite Private Placement would continue in full force and effect as if the Leonite Settlement Agreement had
never been executed, and all rights, remedies, claims, defaults and events of default of Leonite thereunder would be expressly reserved
and preserved. Any portion of the Settlement Payment received by Leonite prior to such termination would be retained by Leonite and applied
against amounts outstanding under the Leonite Note. In such event, we would remain subject to all of our obligations under the Leonite
Note, including payment of up to $10,000,000 in principal, interest at 9% per annum and other amounts, and our assets would remain subject
to Leonite&rsquo;s first-priority security interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were formed as a Delaware
limited liability company on April&nbsp;12, 2018 under the name OS Therapies, LLC.&nbsp;On June&nbsp;24, 2019, we converted from a limited
liability company to a Delaware corporation and changed our name to OS Therapies Incorporated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We presently conduct all of
our operations remotely. Our registered corporate address is 115 Pullman Crossing Road, Suite #103, Grasonville, Maryland 21638, and our
telephone number is (410)&nbsp;297-7793. Our website address is <I>www.ostherapies.com</I>. We make our periodic and current reports that
are filed with the SEC available, free of charge, on our website as soon as reasonably practicable after such material is electronically
filed with, or furnished to, the SEC. Information contained on, or accessible through, our website is not a part of, and is not incorporated
by reference into, this prospectus supplement or the accompanying base prospectus and, therefore, should not be relied upon with respect
to this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_004"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common stock offered by us</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 71%; text-align: justify">500,000 shares.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common stock to be outstanding after this offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">46,125,825 shares.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will not receive any cash proceeds from the sales of the shares of our common stock in this offering. See the section titled &ldquo;Use of Proceeds&rdquo; on page&nbsp;S-7&nbsp;of this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You should read the &ldquo;Risk Factors&rdquo; section of this prospectus supplement, the accompanying base prospectus and in the documents incorporated by reference in this prospectus supplement and the accompanying base prospectus for a discussion of factors to consider before deciding to purchase shares of our common stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NYSE American symbol</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OSTX</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares of common
stock that will be outstanding immediately after this offering as shown above is based on 45,625,825 shares of common stock outstanding
as of August 5, 2026, and excludes, in each case as of such date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,401,786 shares of our common stock issuable upon the conversion of outstanding shares of our Series A senior convertible preferred stock, with a current conversion ratio of 3.571429 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,659,585
shares of our common stock issuable upon the exercise of outstanding warrants;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,424,108
shares of our common stock issuable upon the exercise of outstanding pre-funded warrants; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,422,500
shares of our common stock issuable upon the exercise of outstanding stock options under our 2023 Incentive Compensation Plan.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
all information in this prospectus supplement assumes no conversion or exercise, as applicable, of our outstanding shares of our Series
A senior convertible preferred stock, warrants or stock options described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_005"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>An investment in our common
stock involves a high degree of risk. You should carefully consider the risks described under &ldquo;Risk Factors&rdquo; in the accompanying
prospectus and our most recent Annual Report on Form 10-K, as well as any amendment or update to our risk factors reflected in subsequent
filings with the SEC, and all of the other information contained in this prospectus supplement and the accompanying base prospectus, and
incorporated by reference into this prospectus supplement and the accompanying base prospectus, including our consolidated financial statements
and related notes, before investing in our common stock. If any of the possible adverse events described below or in those sections actually
occur, our business, business prospects, cash flow, results of operations or financial condition could be harmed, the trading price of
our common stock could decline, and you might lose all or part of your investment in our common stock. Additional risks and uncertainties
not presently known to us or that we currently deem immaterial may also impair our operations and results.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Common Stock and this
Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our stock price may be volatile and subject
to broad market and industry fluctuations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock markets in general,
and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have historically experienced significant
volatility. Factors such as inflation, rising interest rates, instability in the global banking sector, and other macroeconomic or geopolitical
events can affect stock prices independently of a company&rsquo;s operating performance. In addition, the trading price of our common
stock may be negatively impacted by third parties seeking to profit from a decline in our stock price, including short sellers, whose
activities could exert downward pressure on the market price. As a result, the market price of our common stock may decline substantially,
regardless of our actual financial results or business performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Sales of a substantial number of shares
of our common stock, including those issued in this offering, could cause the market price of our common stock to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sale of a substantial
number of shares of our common stock in the public market, or the perception that such sales may occur, could cause the market price of
our common stock to decline. Based on our shares outstanding as of August 5, 2026, we would have 46,125,825 shares of common stock outstanding
(excluding any shares issuable upon the conversion or exercise, as applicable, of the Bridge Note, our outstanding Series A senior convertible
preferred stock, warrants or stock options) following the completion of this offering. A substantial majority of the outstanding shares
of our common stock are, and all of the shares sold in this offering upon issuance will be, freely tradable without restriction or further
registration under the Securities Act, unless such shares are owned or purchased by &ldquo;affiliates&rdquo; as that term is defined in
Rule&nbsp;144 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, as of August
5, 2026, there were outstanding (i) 392,500 shares of Series A senior convertible preferred stock convertible into an aggregate of 1,401,786
shares of common stock, (ii) warrants to purchase an aggregate of 16,083,693 shares of common stock (including pre-funded warrants to
purchase 2,424,108 shares of common stock), and (iii)&nbsp;stock options to purchase an aggregate of 8,422,500 shares of our common stock,
of which options to purchase 2,400,000 shares of our common stock were then exercisable. The shares of our common stock issuable upon
conversion or exercise, as applicable, of such securities may be immediately eligible for resale in the open market. Any such sales, or
the perception that such sales could occur, could cause the market price of our common stock to decline and may make it more difficult
for us to raise capital in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You will experience immediate and substantial
dilution.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The price per share in this
offering may exceed the net tangible book value (deficit) per share of our common stock outstanding prior to this offering. Based on an
offering price of $1.60 per share (the closing price of our common stock on the NYSE American on August 5, 2026), you will experience
immediate dilution of $1.85 per share, representing the difference between the effective offering price per share and our pro forma, as
adjusted net tangible book value (deficit) per share as of March 31, 2026 after giving effect to the 2026 Registered Direct Offering,
the Bridge Conversions, the Leonite Private Placement, the August Bridge Financing, the Settlement Payment and this offering. In addition,
we are not restricted from issuing additional securities in the future, including shares of common stock, securities that are convertible
into or exchangeable for, or that represent the right to receive, common stock or substantially similar securities. The issuance of these
securities may cause further dilution to our stockholders. The conversion of outstanding shares of our Series A senior convertible preferred
stock and the exercise of outstanding warrants and stock options may also result in further dilution of your investment. See the section
entitled &ldquo;Dilution&rdquo; below for a more detailed illustration of the dilution you may incur if you participate in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s_006"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not receive any cash
proceeds from the sale of the shares of our common stock in this offering. The Settlement Shares are being issued as non-cash consideration
to Leonite in partial satisfaction of all amounts outstanding under the Leonite Note and the other transaction documents entered into
in connection with the Leonite Private Placement, in accordance with the Leonite Settlement Agreement. See &ldquo;Prospectus Supplement
Summary&mdash;Recent Developments&mdash;Leonite Settlement&rdquo; for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s_007"></A><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation
of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare cash dividends
will be made at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements,
general business conditions, contractual limitations and other factors that our board of directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s_008"></A><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you invest in this offering,
your ownership interest will be immediately diluted to the extent of the difference between the offering price per share and the pro forma,
as adjusted net tangible book value (deficit) per share after giving effect to the pro forma adjustments described below and this offering.
We calculate net tangible book value (deficit) per share by dividing the net tangible book value (deficit), which is the total tangible
assets less total liabilities, by the number of outstanding shares of our common stock. Dilution represents the difference between the
offering price per share in this offering and the pro forma, as adjusted net tangible book value (deficit) per share of our common stock
immediately after giving effect to the pro forma adjustments described below and this offering. Our net tangible book deficit as of March
31, 2026 was approximately $(17.2) million, or $(0.44) per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our pro forma net tangible
book deficit as of March 31, 2026 was $(12.9) million, or $(0.29) per share. Pro forma net tangible book deficit represents the amount
of our total tangible assets less our total liabilities, after giving effect to (i) the 2026 Registered Direct Offering, including the
receipt of net proceeds of approximately $4.8 million therefrom and issuance of 2,505,073 shares of our common stock, (ii) the Bridge
Conversions and resulting issuance of 1,576,311 shares of our common stock, (iii) the Leonite Private Placement and the receipt of net
proceeds of approximately $1.6 million therefrom, (iv) the August Bridge Financing and the receipt of net proceeds of approximately $2.2
million therefrom, and (v) the Settlement Payment of $1.9 million in cash. Pro forma net tangible book deficit per share represents pro
forma net tangible book deficit divided by the total number of our outstanding shares of common stock as of March 31, 2026 after giving
effect to the pro forma adjustments described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect to (i)
the pro forma adjustments described above, (ii) the extinguishment of the Leonite Note and the resulting loss on extinguishment, and (iii)
the issuance and sale of 500,000 shares of our common stock in this offering at an offering price of $1.60 per share (the closing price
of our common stock on the NYSE American on August 5, 2026), we would have had a pro forma, as adjusted net tangible book deficit as of
March 31, 2026 of approximately $(11.4) million, or $(0.25) per share. This represents an immediate increase in the net tangible book
value (deficit) of $0.04 per share to our existing stockholders and an immediate dilution in net tangible book value (deficit) of $1.85
per share to Leonite.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table illustrates
this per share dilution based on 39,278,192 shares of common stock outstanding as of March 31, 2026:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Offering price per share</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">1.60</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Net tangible book deficit per share as of March 31, 2026</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(0.44</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 9pt">Increase per share attributable to the pro forma adjustments</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.15</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Pro forma net tangible book deficit per share as of March 31, 2026</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(0.29</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 9pt">Increase in pro forma net tangible book value per share attributable to this offering</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.04</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Pro forma, as adjusted net tangible book deficit per share as of March 31, 2026</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.25</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Dilution per share to new investors participating in this offering</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.85</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above discussion and table
are based on 39,278,192 shares of common stock outstanding as of March 31, 2026 and exclude, as of such date, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,401,786 shares of our common stock issuable upon the conversion of outstanding shares of our Series A senior convertible preferred stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,033,005 shares of our common stock issuable upon the exercise of outstanding warrants;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,172,693 shares of our common stock issuable upon the exercise of outstanding pre-funded warrants; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,357,500 shares of our common stock issuable upon the exercise of outstanding stock options under our 2023 Incentive Compensation Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that any of
these shares of preferred stock, warrants or stock options are converted or exercised, as applicable, new options are issued under our
2023 Incentive Compensation Plan and subsequently exercised or we issue additional shares of common stock or securities convertible and
exercisable into shares of common stock in the future, there will be further dilution to investors participating in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_009"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are selling 500,000 shares
of our common stock pursuant to this prospectus supplement and the accompanying base prospectus directly to Leonite as part of the consideration
for the transactions contemplated by the Leonite Settlement Agreement. We expect that the sale of the shares of our common stock will
be completed on or about August 6, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not receive any proceeds
from the sale of the shares of our common stock in this offering. The Settlement Shares constitute a portion of the consideration for
the transactions contemplated by the Leonite Settlement Agreement and are being issued directly by us to Leonite without the use of any
placement agent, underwriter or broker-dealer. The expenses of such issuance are estimated at $25,000 and are payable by us. We are not
paying any underwriting discounts or commissions in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Leonite is not acting as an
underwriter within the meaning of Section 2(a)(11) of the Securities Act in connection with this offering. The Settlement Shares are being
acquired by Leonite as consideration for the Leonite Settlement and not with a view to, or for sale in connection with, any distribution
thereof. However, Leonite may resell the Settlement Shares from time to time in the open market, in privately negotiated transactions
or otherwise, at market prices prevailing at the time of sale, at prices related to the prevailing market price, at negotiated prices
or otherwise. Any such resales by Leonite will be made in compliance with the Securities Act and applicable state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is traded
on the NYSE American under the trading symbol &ldquo;OSTX.&rdquo; The transfer agent for our common stock is VStock Transfer, LLC, Woodmere,
New&nbsp;York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_010"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Olshan Frome Wolosky LLP,
New York, New York, will pass upon the validity of the issuance of the common stock offered by this prospectus supplement as our counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_011"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements of OS Therapies Incorporated incorporated in this prospectus supplement by reference to the Annual Report on Form 10-K for
the year ended December 31, 2025 have been so incorporated in reliance on the report, which contains an explanatory paragraph regarding
the Company&rsquo;s ability to continue as a going concern, of MaloneBailey, LLP, an independent registered public accounting firm, given
on the authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_012"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC
a registration statement on Form S-3, of which this prospectus supplement and the accompanying base prospectus are a part, under the Securities
Act, to register the shares of common stock offered by this prospectus supplement. However, this prospectus supplement and the accompanying
base prospectus do not contain all of the information contained in the registration statement and the exhibits and schedules to the registration
statement. We encourage you to carefully read the registration statement and the exhibits and schedules to the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the reporting
requirements of the Exchange Act and file annual, quarterly and current reports, proxy statements and other information with the SEC.
The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding issuers
that file electronically with the SEC, including our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is traded
on the NYSE American under the symbol &ldquo;OSTX.&rdquo; General information about our company, including our Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as any amendments and exhibits to those reports, are available
free of charge through our website at www.ostherapies.com as soon as reasonably practicable after we file them with, or furnish them to,
the SEC. Information on, or that can be accessed through, our website is not incorporated into this prospectus supplement or other securities
filings and is not a part of these filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s_013"></A><B>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We &ldquo;incorporate by reference&rdquo;
into this prospectus supplement the information we file with the SEC, which means that we can disclose important information to you by
referring you to those documents. The information incorporated by reference is an important part of this prospectus supplement and information
that we file subsequently with the SEC will automatically update this prospectus supplement. We incorporate by reference the documents
listed below and any filings we make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act after initial filing of
the registration statement that contains the prospectus and prior to the time that we sell all the securities offered by this prospectus
supplement (in each case, except for the information furnished under Item 2.02 or Item 7.01 in any current report on Form 8-K and Form
8-K/A):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Annual Report on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390026036629/ea0283146-10k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended December 31, 2025, filed with the SEC on March 31, 2026;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">Our Definitive Proxy Statement on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001795091/000121390026081390/ea0298814-01.htm">Schedule 14A</A>, filed with the SEC on July 24, 2026;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Quarterly Report on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001795091/000121390026058070/ea0290259-10q_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-Q</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the quarter ended March 31, 2026, filed with the SEC on May 18, 2026;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Our Current Reports on Form 8-K (only to the extent &ldquo;filed&rdquo;
and not &ldquo;furnished&rdquo;) filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390026003166/ea0272516-8k_ostherap.htm">January
12, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390026016408/ea0276846-8k_ostherap.htm">February
13, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390026024726/ea0280014-8k_ostherapies.htm">March
6, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390026037476/ea0283924-8k_ostherapies.htm">March 31,
2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001795091/000121390026039529/ea0284488-8k_ostherapies.htm">April 2,
2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001795091/000121390026075013/ea0296868-8k_ostherapies.htm">July 2,
2026</A> (as amended on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001795091/000121390026075781/ea0297249-8ka1_ostherapies.htm">July
7, 2026</A>) and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001795091/000121390026082876/ea0299692-8k_ostherapies.htm">July
29, 2026</A>; and</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of our registered securities contained in </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390026036629/ea028314601ex4-9.htm" STYLE="-sec-extract: exhibit">Exhibit 4.9</A></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to our Annual Report on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390026036629/ea0283146-10k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended December 31, 2025, filed with the SEC on March 31, 2026, including any amendment or reports filed for the purpose of updating this description.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may request a copy of
these filings (other than an exhibit to a filing unless that exhibit is specifically incorporated by reference into that filing) at no
cost, by writing to or telephoning us at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OS Therapies Incorporated</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">115 Pullman Crossing Road, Suite 103</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Grasonville, Maryland 21638</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attention: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(410) 297-7793</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea029753101_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$100,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SENIOR DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBORDINATED DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
offer and sell any combination of the securities described in this prospectus in one or more offerings. The securities we may offer may
be convertible into or exercisable or exchangeable for other securities. We may offer the securities separately or together, in separate
classes or series and in amounts, at prices and on terms that will be determined at the time the securities are offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, certain selling
stockholders may from time to time offer and sell shares of our common stock. We will not receive any of the proceeds from the sale of
shares of our common stock by selling stockholders, if any, pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus describes
some of the general terms that may apply to these securities. Each time securities are sold, the specific terms and amounts of the securities
being offered, and any other information relating to the specific offering will be set forth in a supplement to this prospectus. We may
also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. In any prospectus supplement
relating to any sales by the selling stockholders, we will, among other things, identify the number of shares of our common stock that
the selling stockholders will be selling. The prospectus supplement and any related free writing prospectus may also add, update or change
information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related
free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered.
This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our shares of common stock
trade on the NYSE American under the symbol &ldquo;OSTX.&rdquo; On August 25, 2025, the closing price of our common stock was $2.19. The
applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, of the securities covered
by the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We, or any selling stockholders
as it only relates to shares of common stock, may offer and sell our securities to or through one or more underwriters, dealers and agents,
or directly to purchasers, on an immediate, continuous or delayed basis. The names of any underwriters, dealers or agents and the terms
of the arrangements with such entities will be stated in the accompanying prospectus supplement. See the sections of this prospectus entitled
&ldquo;About this Prospectus&rdquo; and &ldquo;Plan of Distribution&rdquo; for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our securities
involves a high degree of risk. You should review carefully the risks and uncertainties referenced under the heading &ldquo;Risk Factors&rdquo;
on page 3 of this prospectus as well as those contained in the applicable prospectus supplement and any related free writing prospectus,
and in the other documents that are incorporated by reference into this prospectus or the applicable prospectus supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is August 25, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 92%">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">About This Prospectus</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ABOUT THE COMPANY</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">CAUTIONARY STATEMENT Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">USE Of proceeds</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">dESCRIPTION OF OUR cAPITAL sTOCK</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">dESCRIPTION OF oUR dEBT sECURITIES</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DESCRIPTION OF OUR WARRANTS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">DESCRIPTION OF OUR RIGHTS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Description of OUR UNITS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">SELLING STOCKHOLDERS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#b_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#b_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="b_001"></A><B>About
This Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is part of
a registration statement that we filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) under the Securities Act
of 1933, as amended (the &ldquo;Securities Act&rdquo;), using a &ldquo;shelf&rdquo; registration process. Under the shelf registration
process, we may from time to time, offer and sell to the public any or all of the securities described in this prospectus in one or more
offerings for an aggregate offering amount of up to $100,000,000. In addition, under this shelf registration process, selling stockholders
may from time to time sell shares of our common stock in one or more offerings. Before purchasing any securities, you should read this
prospectus and any applicable prospectus supplement together with the additional information described under the headings &ldquo;Where
You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus only provides
you with a general description of the securities we and/or the selling stockholders may offer. Each time we sell a type or series of securities
under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of the offering,
including the specific amounts, prices and terms of the securities offered. We may also authorize one or more free writing prospectuses
to be provided to you that may contain material information relating to these offerings. This prospectus may not be used to sell our securities
unless accompanied by a prospectus supplement. Each such prospectus supplement and any free writing prospectus that we may authorize to
be provided to you may also add, update or change information contained in this prospectus or in documents incorporated by reference into
this prospectus. If this prospectus is inconsistent with the prospectus supplement or free writing prospectus, you should rely upon the
prospectus supplement or free writing prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus contains summaries
of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete
information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to
herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus
is a part, and you may obtain copies of those documents as described below under the heading &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus incorporates
by reference, and any prospectus supplement or free writing prospectus may contain and incorporate by reference, market data and industry
statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe
these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified
this information. In addition, the market and industry data and forecasts that may be included or incorporated by reference in this prospectus,
any prospectus supplement or any applicable free writing prospectus may involve estimates, assumptions and other risks and uncertainties
and are subject to change based on various factors, including those discussed under the heading &ldquo;Risk Factors&rdquo; contained in
this prospectus, the applicable prospectus supplement and any applicable free writing prospectus, and under similar headings in other
documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this prospectus, except
as otherwise indicated, the words &ldquo;OS Therapies&rdquo; or the &ldquo;Registrant&rdquo; refer to OS Therapies Incorporated and the
words &ldquo;company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to OS Therapies, together with its consolidated
subsidiaries. In this prospectus, references to &ldquo;securities&rdquo; collectively means our common stock, preferred stock, warrants,
debt securities, or any combination of the foregoing securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on information
contained or incorporated by reference in this prospectus. Neither we, any selling stockholders, nor any underwriters have authorized
any person to provide you with information that differs from what is contained or incorporated by reference in this prospectus. If any
person does provide you with information that differs from what is contained or incorporated by reference in this prospectus, you should
not rely on it. This prospectus is not an offer to sell or the solicitation of an offer to buy any securities other than the securities
to which it relates, or an offer or solicitation in any jurisdiction where offers or sales are not permitted. The information contained
in this prospectus is accurate only as of the date of this prospectus, even though this prospectus may be delivered or shares may be sold
under this prospectus on a later date. Our business, financial condition, results of operation and prospects may have changed since those
dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_002"></A>about
the company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OS Therapies Incorporated
is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma
(OS) and other solid tumors. Our mission is to address the significant need for new treatments in cancers of the bone in children and
young adults. Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to its
location, changing genotypes and high metastases rates. We are currently seeking to answer the call for new treatments that will prevent
metastasis and the recurrence of metastases with our lead core product candidate OST-HER2 (also known as OST31-164), a cancer immunotherapy
product candidate that produces a cellular immune response against the cancer antigen HER2. In 2021, we opened a clinical study to produce
data for the U.S.&nbsp;Food and Drug Administration (FDA) to evaluate the safety and efficacy of OST-HER2 in patients after resection
of recurrent Osteosarcoma, which achieved full enrollment of 41 patients in October&nbsp;2023. In the first quarter of 2025, we announced
that our Phase&nbsp;IIb clinical trial achieved its primary endpoint with statistical significance. We believe the efficacy results, combined
with the favorable safety profile and the unmet clinical need, support the potential for regulatory approval. In June 2025, we participated
in a Type D meeting with the FDA and subsequently received positive written feedback regarding the design and endpoints of our Phase IIb
trial of OST-HER2 to support a potential Biologics License Application (BLA). Based on this feedback, we have submitted a Breakthrough
Therapy Designation request and, subject to continued positive regulatory guidance, plan to submit a BLA for OST-HER2 following our End
of Phase 2 meeting with the FDA, anticipated in the third quarter of 2025. Upon success in gaining regulatory approval from the FDA with
OST-HER2 in Osteosarcoma, we intend to evaluate OST-HER2&rsquo;s potential use, both alone and in combination with HER2 targeting antibodies
such as Herceptin&reg;, in other solid tumors including breast, esophageal and lung cancers. OST-HER2 has potential uses in both the prevention
of metastases in solid tumors, and therapeutically against HER2-expressing solid tumors treated with HER targeting antibodies. In addition
to our development of OST-HER2 for multiple indications of solid cancers in humans, OST-HER2 is a product candidate for veterinary use
in canines. As part of our growth strategies, we intend to consider potentially out-licensing OST-HER2 to animal health companies for
such use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also own rights to OST-Tunable
Drug Conjugate (OST-tADC) platform, a next generation antibody-drug conjugate (ADC) silicone dioxide linker technology. &ldquo;Tunable&rdquo;
is a term used in drug development that refers to the properties that can be influenced by chemical modifications, and &ldquo;antibody-drug
conjugate&rdquo; or ADC is a term used to describe a drug made up of a monoclonal antibody attached to a cytotoxic payload, or a highly
active and toxic pharmaceutical molecule, through chemical linkers. The ADC links an antibody that can home in on a targeted tumor to
deploy the cytotoxic payload or toxic agent against the tumor. Furthering our founding mission, we intend to investigate clinical indications
for OST-tADC in Osteosarcoma and other solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Implications of Being an Emerging Growth Company and Smaller Reporting
Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We qualify as an &ldquo;emerging
growth company&rdquo; as defined in the Jumpstart Our Business Startups Act&nbsp;of&nbsp;2012 (the &ldquo;JOBS Act&rdquo;). For as long
as we remain an emerging growth company, we may take advantage of specified reduced reporting requirements and other burdens that are
otherwise applicable generally to other public companies. These provisions include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced obligations with respect to financial data, including presenting only two&nbsp;years of audited financial statements and selected financial data, and only two&nbsp;years of related Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations disclosure in our initial registration statement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act&nbsp;of&nbsp;2002, as amended;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced disclosure about executive compensation arrangements in our periodic reports, registration statements and proxy statements; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions from the requirements to seek non-binding advisory votes on executive compensation or stockholder approval of any golden parachute arrangements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may take advantage of some
or all of these provisions until we are no longer an emerging growth company. We will remain an emerging growth company until the earliest
of (i)&nbsp;the last&nbsp;day the fiscal year following the fifth anniversary of the completion of our initial public offering, (ii)&nbsp;the
last&nbsp;day of the first fiscal year in which our annual gross revenues exceed $1.235&nbsp;billion, (iii)&nbsp;the date on which we
have, during the immediately preceding three-year period, issued more than $1.0&nbsp;billion in non-convertible debt securities and (iv)&nbsp;the
date on which we are deemed to be a large accelerated filer under the rules of the SEC.&nbsp;We may choose to take advantage of some but
not all of these reduced burdens. For example, we have taken advantage of the reduced reporting requirements with respect to disclosure
regarding our executive compensation arrangements, have presented only two&nbsp;years of audited financial statements and only two&nbsp;years
of related &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; disclosure incorporated
by reference in this prospectus, and have taken advantage of the exemption from auditor attestation on the effectiveness of our internal
control over financial reporting. To the extent that we take advantage of these reduced burdens, the information that we provide stockholders
may be different than you might obtain from other public companies in which you hold shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the JOBS Act
permits emerging growth companies to take advantage of an extended transition period to comply with new or revised accounting standards
applicable to public companies. We have elected to use this extended transition period. As a result of this election, our timeline to
comply with new or revised accounting standards will in many cases be delayed as compared to other public companies that are not eligible
to take advantage of this election or have not made this election. Therefore, our financial statements may not be comparable to those
of companies that comply with the public company effective dates for these accounting standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also a &ldquo;smaller
reporting company&rdquo; as defined in the Securities Exchange&nbsp;Act&nbsp;of&nbsp;1934, as amended (the &ldquo;Exchange&nbsp;Act&rdquo;),
and have elected to take advantage of certain of the scaled disclosures available to smaller reporting companies. To the extent that we
continue to qualify as a &ldquo;smaller reporting company&rdquo; as such term is defined in Rule&nbsp;12b-2 under the Exchange&nbsp;Act,
after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an &ldquo;emerging growth company&rdquo;
may continue to be available to us, including exemption from compliance with the auditor attestation requirements pursuant to the Sarbanes-Oxley
Act and reduced disclosure about our executive compensation arrangements. We will continue to be a &ldquo;smaller reporting company&rdquo;
until we have $250&nbsp;million or more in public float (based on our common stock) measured as of the last business&nbsp;day of our most
recently completed second fiscal quarter or, in the event we have no public float (based on our common stock) or a public float (based
on our common stock) that is less than $700&nbsp;million, annual revenues of $100&nbsp;million or more during the most recently completed
fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were formed as a Delaware
limited liability company on April&nbsp;12, 2018 under the name OS Therapies, LLC.&nbsp;On June&nbsp;24, 2019, we converted from a limited
liability company to a Delaware corporation and changed our name to OS Therapies Incorporated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We presently conduct all of
our operations remotely. Our registered corporate address is 115 Pullman Crossing Road, Suite #103, Grasonville, Maryland 21638, and our
telephone number is (410)&nbsp;297-7793. Our website address is <I>www.ostherapies.com</I>. We make our periodic and current reports that
are filed with the SEC available, free of charge, on our website as soon as reasonably practicable after such material is electronically
filed with, or furnished to, the SEC. Information contained on, or accessible through, our website is not a part of, and is not incorporated
by reference into, this prospectus or any accompanying prospectus supplement.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_003"></A>Risk
Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investing in our securities
involves a high degree of risk. Before making a decision to invest in our securities, you should carefully consider the risks described
under the heading &ldquo;Risk Factors&rdquo; in the applicable prospectus supplement and any related free writing prospectus, and under
similar headings in our most recent annual report on Form 10-K, and in subsequent quarterly reports on Form 10-Q filed subsequent to such
Form 10-K, as well as any amendments thereto, which are incorporated by reference into this prospectus and the applicable prospectus supplement
in their entirety, together with other information in this prospectus and the applicable prospectus supplement, the documents incorporated
by reference herein and therein, and any free writing prospectus that we may authorize for use in connection with a specific offering.
See &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_004"></A><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus, any prospectus
supplement and any related free writing prospectus, including the information incorporated by reference herein and therein, contain forward-looking
statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Any statements about our expectations,
beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements
are often, but are not always, made through the use of words or phrases such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo;
&ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo;
&ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;seek,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo;
&ldquo;will,&rdquo; &ldquo;would,&rdquo; or the negative of these words or other comparable terminology. Accordingly, these statements
involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given these uncertainties,
you should not place undue reliance on these forward-looking statements as actual events or results may differ materially from those projected
in the forward-looking statements due to various factors, including, but not limited to, those set forth under the heading &ldquo;Risk
Factors&rdquo; in any applicable prospectus supplement, the documents incorporated by reference therein or any free writing prospectus
that we authorized. Our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements
contained in this prospectus, in the documents incorporated by reference herein and in any prospectus supplement by these cautionary statements.
These forward-looking statements speak only as of the date on which the statements were made and are not guarantees of future performance.
Although we undertake no obligation to revise or update any forward-looking statements (except as required by U.S. federal securities
laws), whether as a result of new information, future events or otherwise, you are advised to review any additional disclosures we make
in the documents we subsequently file with the SEC that are incorporated by reference in this prospectus and any prospectus supplement.
See &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_005"></A>Use
of Proceeds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated
in a prospectus supplement, we intend to use the net proceeds from the sale of securities offered by this prospectus and any applicable
prospectus supplement for working capital and other general corporate purposes, which may include funding our ongoing and planned clinical
trials, advancing our research and development programs, and acquiring or investing in technologies, product candidates or businesses
that are complementary to our strategic objectives. Until we apply the proceeds from a sale of securities to their intended purposes,
we may invest those proceeds in short-term, interest-bearing, investment-grade, securities or hold as cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not receive any of
the proceeds from the sale of shares of our common stock by selling stockholders, if any, pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_006"></A><B>DESCRIPTION OF OUR CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following summary of
the material terms of our securities is not intended to be a complete summary of the rights and preferences of such securities, and is
qualified by reference to our third amended and restated certificate of incorporation, as amended (&ldquo;certificate of incorporation&rdquo;),
our certificate of designation, preferences, rights and limitations of Series A senior convertible preferred stock (the &ldquo;certificate
of designation&rdquo;), our amended and restated bylaws, as amended (&ldquo;bylaws&rdquo;), and the warrant-related documents described
herein, which are exhibits to the registration statement of which this prospectus is a part. We urge you to read each of our certificate
of incorporation, our bylaws and the warrant-related documents described herein in their entirety for a complete description of the rights
and preferences of our securities.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorized Capital Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized capital stock
currently consists of 50,000,000&nbsp;shares of common stock, par value $0.001 per share, and 5,000,000&nbsp;shares of preferred stock,
par value $0.001 per share, of which 2,500,000 shares of which are designated as Series A senior convertible preferred stock, par value
$0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of our common
stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock
do not have any cumulative voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our common stock
are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject
to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or
other subscription rights or redemption or sinking fund provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of our liquidation,
dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all
debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares of common stock to be issued
by us in this offering will be, when issued and paid for, validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our shares of common stock
are traded on the NYSE American under the symbol &ldquo;OSTX.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our common stock is VStock Transfer, LLC, Woodmere, New&nbsp;York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
the authority, without further action by our stockholders, to issue up to 5,000,000&nbsp;shares of preferred stock in one or more series
and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend
rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting,
or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred
stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments
and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing
a change in control of our company or other corporate action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Series A Senior Convertible Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our certificate of designation
sets forth the rights, preferences and limitations of our Series A senior convertible preferred stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the right of the holder to convert such shares of Series A senior convertible preferred stock into shares of our common stock, with mandatory conversion upon (i) a qualified firm commitment underwritten public offering of common stock raising gross proceeds in excess of $10.0 million, with a per share price not less than $12.00, (ii) a qualified PIPE financing raising gross proceeds in excess of $20.0 million, with a per share price not less than $12.00, (iii) a closing of a third-party acquisition where all outstanding shares of common stock (including the shares of common stock issued pursuant to the mandatory conversion of the Series A senior convertible preferred stock) are purchased or exchanged by an unaffiliated third party and in which the consideration paid to all holders of outstanding shares of common stock for such purchase or exchange consists solely of cash at a purchase price per share of common stock not less than $12.00, or (iv) such time as the daily VWAP for the common stock is greater than 300% of the then applicable conversion price for a period of 20 consecutive trading days with minimum average daily trading volume of $2.0 million;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a liquidation preference of 150% of the original issue price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the right to one vote per share and vote together with the common stock on an as-converted&nbsp;basis (subject to a voting price floor equal to $3.78), except that holders of Series A senior convertible preferred stock shall vote as a separate class with respect to certain specified matters; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such other terms and provisions as are set forth in the certificate of designation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each share of Series A senior
convertible preferred stock is convertible into a number of shares of common stock at a conversion ratio equal to (A) the original issue
price of the Series A senior convertible preferred stock divided by (B) the conversion price of the Series A senior convertible preferred
stock. The original issue price and the conversion price of the Series A senior convertible preferred stock will initially be $4.00 (resulting
in an initial conversion ratio of 1:1) and are subject to adjustment as set forth in the certificate of designation. The Series A Preferred
Stock will not be traded on any securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The conversion price of the
Series A senior convertible preferred stock was automatically reset to $1.12 per share on April 23, 2025 and is subject to further adjustment
upon the occurrence of certain events, including the sale of equity securities by us at an effective price per share less than the then
conversion price during the two-year&nbsp;period beginning from the initial issuance date, subject to certain exceptions (the &ldquo;Series
A Dilutive Issuances&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Ayala Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the acquisition
of the&nbsp;<I>Lm</I>-based immune-oncology programs and related intellectual property assets from Ayala Pharmaceuticals, Inc. (&ldquo;Ayala&rdquo;),
we issued to Ayala a warrant to purchase 2,166,381&nbsp;shares of common stock. The warrant is exercisable upon issuance at an exercise
price per share of $0.001 (as adjusted from time to time in accordance with the terms thereof) and will expire three years from the date
of issuance. This warrant may not be exercised to the extent that the holder, together with its affiliates, would beneficially own more
than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. The holder may increase
or decrease this percentage, but not in excess of 19.99%, unless and until we obtain stockholder approval as required by NYSE American
LLC Company Guide Section 713.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>IPO Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We issued warrants to Brookline
Capital Markets, a division of Arcadia Securities, LLC, the representative of the underwriters in our initial public offering, to purchase
an aggregate of 112,000 shares of common stock at an exercise price of $4.40 per share. These warrants are currently exercisable and have
a cashless exercise provision and will terminate on the fifth anniversary of July 31, 2024. These warrants also provide for customary
anti-dilution&nbsp;provisions, a single demand registration right, and immediate &ldquo;piggyback&rdquo; registration rights with respect
to the registration of the shares of common stock underlying the warrants, with a term of such demand and &ldquo;piggyback&rdquo; registration
rights not exceeding five&nbsp;years from July 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Series A Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December&nbsp;31, 2024
and January&nbsp;14, 2025, we issued warrants exercisable into 7,211,303&nbsp;shares of common stock at an exercise price of $1.12 per
share, subject to adjustment as set forth therein. The exercise price of these warrants is subject to the Series A Dilutive Issuances.
These warrants are exercisable by the holder for a period of five years from April&nbsp;9, 2025. As of August 8, 2025, warrants to purchase
3,446,308 shares of common stock remain outstanding and exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>New Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From June 23 to July 11, 2025,
we issued warrants to purchase an aggregate of 3,764,995 shares of common stock at an exercise price of $3.00 per share, subject to adjustment
as set forth therein. These warrants are immediately exercisable from the date of issuance and have a term of exercise of five years from
such date. The exercise price and number of shares issuable upon exercise of these warrants are subject to appropriate adjustment in the
event of stock dividends, stock splits, subsequent rights offerings, pro rata distributions, reorganizations or similar events affecting
our common stock and the exercise price. The exercise price of these warrants is also subject to adjustment upon the occurrence of subsequent
sales of equity securities by us during such time any of these warrants are outstanding at an effective price per share less than the
exercise price of these warrants then in effect (such lower price, the &ldquo;Dilutive Issuance Price&rdquo; and such issuances, collectively,
&ldquo;Dilutive Issuances&rdquo;), subject to certain exceptions. In the event of a Dilutive Issuance, the exercise price will be reduced
to the greater of (x) such lower Dilutive Issuance Price and (y) $1.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These warrants also provide
that, at any time any of these warrants are outstanding, if the closing price of our common stock on the applicable trading market equals
or exceeds 300% of the exercise price then in effect for any 20 consecutive trading days, we may, subject to the satisfaction of certain
equity conditions, require the holder to exercise all or a portion of the warrants for cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Effects of Our Certificate of Incorporation and Bylaws
and Delaware Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our certificate of incorporation
and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control
of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board
of directors rather than pursue non-negotiated&nbsp;takeover attempts. These provisions include the items described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Board composition and
filling vacancies. </I></B>Our certificate of incorporation provides that directors may be removed with or without cause only by the affirmative
vote of the holders of two-thirds&nbsp;or more of the shares then entitled to vote at an election of directors. Further, any vacancy on
our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled
by the affirmative vote of a majority of our directors then in office even if less than a quorum. The limitations on removal of directors
and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>No written consent of
stockholders. </I></B>Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the
stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This
limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of
directors by our stockholders without holding a meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Meetings of stockholders.</I></B>
Our certificate of incorporation and bylaws provide that a special meeting of stockholders may be called only by resolution adopted by
our board of directors, chairman of the board of directors or chief executive officer or upon the written request of stockholders owning
at least 33&amp;frac13;% of the outstanding common stock and only those matters set forth in the notice of the special meeting may be
considered or acted upon at a special meeting of stockholders. Stockholders owning less than 33&amp;frac13;% may not call a special meeting,
which may delay the ability of our stockholders to force consideration of a proposal or for holders controlling a majority of our capital
stock to take any action, including the removal of directors. Our bylaws limit the business that may be conducted at an annual meeting
of stockholders to those matters properly brought before the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Advance notice requirements.
</I></B>Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for
election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder
proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally,
to be timely, notice must be received at our principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior
to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and content
of all stockholders&rsquo; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual
or special meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Amendment to certificate
of incorporation and bylaws. </I></B>Any amendment of our certificate of incorporation must first be approved by a majority of our board
of directors, and if required by law or our certificate of incorporation, must thereafter be approved by a majority of the outstanding
shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except
that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by
not less than two-thirds&nbsp;of the outstanding shares entitled to vote on the amendment, and not less than two-thirds&nbsp;of the outstanding
shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors
then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of a majority of the
outstanding shares entitled to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating
to notice of stockholder business and nominations and special meetings must be approved by not less than two-thirds&nbsp;of the outstanding
shares entitled to vote on the amendment, and not less than two-thirds&nbsp;of the outstanding shares of each class entitled to vote thereon
as a class, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority
of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Undesignated preferred
stock. </I></B>Our certificate of incorporation provides for 5,000,000 authorized shares of preferred stock. The existence of authorized
but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of
a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors
were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares
of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute
the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of
incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred
stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders
of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and
may have the effect of delaying, deterring or preventing a change in control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations on Liability and Indemnification
of Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our certificate of incorporation
and bylaws provide indemnification for our directors and officers to the fullest extent permitted by the Delaware General Corporation
Law. We have entered into indemnification agreements with each of our directors that may, in some cases, be broader than the specific
indemnification provisions contained under Delaware law. In addition, as permitted by Delaware law, our certificate of incorporation includes
provisions that eliminate the personal liability of our directors and officers for monetary damages resulting from breaches of certain
fiduciary duties as a director or officer, as applicable, except to the extent such an exemption from liability thereof is not permitted
under the Delaware General Corporation Law. The effect of these provisions is to restrict our rights and the rights of our stockholders
in derivative suits to recover monetary damages against a director or officer for breach of fiduciary duties as a director or officer,
subject to certain exceptions in which case the director or officer would be personally liable. An officer may not be exculpated for any
action brought by or in the right of the corporation. A director may not be exculpated for improper distributions to stockholders. Further,
pursuant to Delaware law a director or officer may not be exculpated for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any breach of his or her duty of loyalty to us or our stockholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any transaction from which the director or officer derived an improper personal benefit.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These limitations of liability
do not apply to liabilities arising under the federal or state securities laws and do not affect the availability of equitable remedies
such as injunctive relief or rescission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our bylaws provide that we
will indemnify our directors and officers to the fullest extent permitted by law, and may indemnify employees and other agents. Our bylaws
also provide that we are obligated to advance expenses incurred by a director or officer in advance of the final disposition of any action
or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into separate
indemnification agreements with our directors and officers. These agreements, among other things, require us to indemnify our directors
and officers for any and all expenses (including reasonable attorneys&rsquo; fees, retainers, court costs, transcript costs, fees of experts,
witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees) judgments,
fines and amounts paid in settlement actually and reasonably incurred by such directors or officers or on his or her behalf in connection
with any action or proceeding arising out of their services as one of our directors or officers, or any of our subsidiaries or any other
company or enterprise to which the person provides services at our request provided that such person follows the procedures for determining
entitlement to indemnification and advancement of expenses set forth in the indemnification agreement. We believe that these bylaw provisions
and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The limitation of liability
and indemnification provisions in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against
directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers,
even though an action, if successful, might provide a benefit to us and our stockholders. Our results of operations and financial condition
may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification
provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us, we have been informed
that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At present, there is no pending
litigation or proceeding involving any of our directors or officers as to which indemnification is required or permitted, and we are not
aware of any threatened litigation or proceeding that may result in a claim for indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section&nbsp;203 of the Delaware General Corporation Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the provisions
of Section&nbsp;203 of the Delaware General Corporation Law. In general, Section&nbsp;203 prohibits a publicly held Delaware corporation
from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a three-year&nbsp;period following
the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner.
Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one
of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds&nbsp;of the outstanding voting stock which is not owned by the interested stockholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;203 defines a
business combination to include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any merger or consolidation involving the corporation and the interested stockholder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, Section&nbsp;203
defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation
and any entity or person affiliated with or controlling or controlled by the entity or person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_007"></A>DESCRIPTION OF OUR DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary, together with
the additional information we include in any applicable prospectus supplements, summarizes the material terms and provisions of the debt
securities that we may offer under this prospectus. While the terms we have summarized below will generally apply to any future debt securities
we may offer, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus
supplement. The terms of any debt securities we offer under a prospectus supplement may differ from the terms we describe below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The debt securities may be
either secured or unsecured and will either be senior debt securities or subordinated debt securities. We will issue the senior notes
under the senior indenture which we will enter into with one or more trustees. We will issue the subordinated notes under the subordinated
indenture which we will enter into with one or more trustees. We have filed forms of these documents as exhibits to the registration statement
of which this prospectus forms a part. We use the term &ldquo;indentures&rdquo; to refer to both the senior indenture and the subordinated
indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indentures will be qualified
under the Trust Indenture Act of 1939, as amended, (the &ldquo;Trust Indenture Act&rdquo;). We use the term &ldquo;debenture trustee&rdquo;
to refer to either the senior trustee or the subordinated trustee, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summaries of
the material provisions of the senior notes, the subordinated notes and the indentures are subject to, and qualified in their entirety
by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the
applicable prospectus supplements related to the debt securities that we sell under this prospectus, as well as the complete indenture,
that contain the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior indenture and the subordinated
indenture are identical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will describe in the applicable
prospectus supplement the terms relating to a series of debt securities, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the title;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the principal amount being offered and, if a series, the total amount authorized and the total amount outstanding;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any limit on the amount that may be issued;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether or not we will issue the series of debt securities in global form and, if so, the terms and who the depositary will be;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the maturity date;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the principal amount due at maturity and whether the debt securities will be issued with any original issue discount;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a U.S. person for U.S. federal income tax purposes, and whether we can redeem the debt securities if we have to pay such additional amounts;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the annual interest rate, which may be fixed or variable, or the method for determining the rate, the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether or not the debt securities will be senior or subordinated, and the terms of the subordination of any series of subordinated debt;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the place where payments will be payable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on transfer, sale or other assignment, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date, if any, after which, the conditions upon which, and the price at which we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions, and any other applicable terms of those redemption provisions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions for a sinking fund, purchase or other analogous fund, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&rsquo;s option to purchase, the series of debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the indenture will restrict our ability and/or the ability of our subsidiaries to:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur additional indebtedness;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue additional securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">create liens;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pay dividends and make distributions in respect of our capital stock and the capital stock of our subsidiaries;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">redeem capital stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">place restrictions on our subsidiaries&rsquo; ability to pay dividends, make distributions or transfer assets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make investments or other restricted payments;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell or otherwise dispose of assets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter into sale-leaseback transactions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">engage in transactions with stockholders and affiliates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue or sell stock of our subsidiaries; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">effect a consolidation or merger;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of any material or special U.S. federal income tax considerations applicable to the debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information describing any book-entry features;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the procedures for any auction and remarketing, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if other than U.S. dollars, the currency in which the series of debt securities will be denominated; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, including any events of default that are in addition to those described in this prospectus or any covenants provided with respect to the debt securities that are in addition to those described above, and any terms which may be required by us or advisable under applicable laws or regulations or advisable in connection with the marketing of the debt securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conversion or Exchange Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will set forth in the applicable
prospectus supplements the terms on which a series of debt securities may be convertible into or exchangeable for common stock or other
securities of ours or a third party, including the conversion or exchange rate, as applicable, or how it will be calculated, and the applicable
conversion or exchange period. We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder
or at our option. We may include provisions pursuant to which the number of our securities or the securities of a third party that the
holders of the series of debt securities receive upon conversion or exchange would, under the circumstances described in those provisions,
be subject to adjustment, or pursuant to which those holders would, under those circumstances, receive other property upon conversion
or exchange, for example in the event of our merger or consolidation with another entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consolidation, Merger or Sale</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indentures in the form
initially filed as exhibits to the registration statement of which this prospectus forms a part may contain covenants that restrict our
ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all of our assets. However, any
successor of ours or acquirer of such assets must assume all of our obligations under the indentures and the debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the debt securities are
convertible into our other securities, the person with whom we consolidate or merge or to whom we sell all of our property must make provisions
for the conversion of the debt securities into securities which the holders of the debt securities would have received if they had converted
the debt securities before the consolidation, merger or sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Events of Default Under the Indentures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise specified
in the applicable prospectus supplement, the following are events of default under the indentures with respect to any series of debt securities
that we may issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we fail to pay interest when due and payable and our failure continues for 90 days and the time for payment has not been validly extended;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we fail to pay the principal, or premium, if any, or to make payment required by any sinking fund or analogous fund when due and payable and the time for payment has not been validly extended;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities, and our failure continues for 30 days after we receive notice from the debenture trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if specified events of bankruptcy, insolvency or reorganization occur.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an event of default with
respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above,
the debenture trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series may,
by notice to us in writing (and to the debenture trustee if notice is given by such holders), declare the unpaid principal, premium, if
any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs
with respect to us, the principal amount of and accrued interest, if any, of each series of debt securities then outstanding shall be
due and payable without any notice or other action on the part of the debenture trustee or any holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of a majority
in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to
the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless
we have cured the default or event of default in accordance with the indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms of the
indentures, if an event of default under an indenture shall occur and be continuing, the debenture trustee will be under no obligation
to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series
of debt securities, unless such holders have offered the debenture trustee reasonable indemnity. The holders of a majority in principal
amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding
for any remedy available to the debenture trustee, or exercising any trust or power conferred on the debenture trustee, with respect to
the debt securities of that series, provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to its duties under the Trust Indenture Act, the debenture trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A holder of the debt securities
of any series will only have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek
other remedies, if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the holder has given written notice to the debenture trustee of a continuing event of default with respect to that series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, and such holders have offered reasonable indemnity to the debenture trustee, to institute the proceeding as trustee; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the debenture trustee does not institute the proceeding and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions, within 60 days after the notice, request and offer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These limitations do not apply
to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on the
debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will periodically file
statements with the debenture trustee regarding our compliance with specified covenants in the indentures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Modification of Indenture; Waiver</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and the debenture trustee
may modify an indenture without the consent of any holders with respect to specific matters, including, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to fix any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to comply with the provisions described above under &ldquo;Consolidation, Merger or Sale&rdquo;;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to evidence and provide for the acceptance of appointment under the indenture by a successor trustee;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to provide for uncertificated debt securities in addition to or in place of certificated securities and to make all appropriate changes for such purpose; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to change anything that does not adversely affect the rights of any holder of debt securities of any series in any material respect.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under the indentures,
the rights of holders of debt securities of any series may be changed by us and the debenture trustee with the written consent of the
holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However,
we and the debenture trustee may only make the following changes with the consent of each holder of any outstanding debt securities affected:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extending the fixed maturity of the debt securities of any series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest or reducing any premium payable upon the redemption of any debt securities; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing the percentage of debt securities the holders of which are required to consent to any supplemental indenture.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Discharge</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indentures provide that
we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for certain obligations,
including obligations to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">register the transfer or exchange of debt securities of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">replace mutilated, destroyed, lost or stolen debt securities of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain paying agencies; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compensate and indemnify the debenture trustee.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to exercise our rights
to be discharged, we must deposit with the debenture trustee money or government obligations, or a combination of both, sufficient to
pay all of the principal, premium, if any, and interest on the debt securities of the series on the dates payments are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information Concerning the Debenture Trustee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The debenture trustee, other
than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically
set forth in the applicable indenture. Upon an event of default under an indenture, the debenture trustee must use the same degree of
care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the debenture trustee
is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless
it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Payment and Paying Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless we otherwise indicate
in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the
person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular
record date for the interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will pay principal of,
and any premium and interest on, the debt securities of a particular series at the office of the paying agents designated by us, except
that, unless we otherwise indicate in the applicable prospectus supplement, we may make certain payments by check which we will mail to
the holder or by wire transfer to certain holders. Unless we otherwise indicate in a prospectus supplement, we will designate an office
or agency of the debenture trustee in the city of New York as our sole paying agent for payments with respect to debt securities of each
series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities
of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All money we pay to a paying
agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt securities which remains unclaimed
at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the
debt security thereafter may look only to us for payment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indentures and the debt
securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust
Indenture Act is applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Subordination of Subordinated Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The subordinated debt securities
will be subordinate and junior in priority of payment to certain of our other indebtedness to the extent described in a prospectus supplement.
The indentures in the form initially filed as exhibits to the registration statement of which this prospectus forms a part do not limit
the amount of indebtedness which we may incur, including senior indebtedness or subordinated indebtedness, and do not limit us from issuing
any other debt, including secured debt or unsecured debt. Additional or different subordination provisions may be described in a prospectus
supplement relating to a particular series of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_008"></A>DESCRIPTION OF OUR WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary, together with
the additional information we include in any applicable prospectus supplements, summarizes the material terms and provisions of the warrants
that we may offer under this prospectus, which consist of warrants to purchase our common stock, preferred stock and/or debt securities
in one or more series. Warrants may be offered independently or together with our common stock, preferred stock, debt securities and/or
rights offered by any prospectus supplement and may be attached to or separate from those securities. While the terms we have summarized
below will generally apply to any future warrants we may offer under this prospectus, we will describe the particular terms of any warrants
that we may offer in more detail in the applicable prospectus supplement. The terms of any warrants we offer under a prospectus supplement
may differ from the terms we describe below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will issue the warrants
directly or under a warrant agreement which we will enter into with a warrant agent to be selected by us. Each series of warrants will
be issued under a separate warrant agreement to be entered into between us and a bank or trust company, as warrant agent, all as set forth
in the prospectus supplement relating to the particular issue of offered warrants. We use the term &ldquo;warrant agreement&rdquo; to
refer to any of these warrant agreements. We use the term &ldquo;warrant agent&rdquo; to refer to the warrant agent under any of these
warrant agreements. The warrant agent will act solely as an agent of ours in connection with the warrants and will not act as an agent
for the holders or beneficial owners of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary of material
provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all of the provisions
of the warrant agreement applicable to a particular series of warrants. We urge you to read the applicable prospectus supplements related
to the warrants that we sell pursuant to this prospectus, as well as the complete warrant agreements that contain the terms of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will describe in the applicable
prospectus supplements the terms relating to a series of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If warrants for the purchase
of our common stock or preferred stock are offered, the prospectus supplements will describe the following terms, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the offering price and the aggregate number of warrants offered;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the total number of shares that can be purchased if a holder of the warrants exercises them and, in the case of warrants for preferred stock, the designation, total number and terms of the series of preferred stock that can be purchased upon exercise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation and terms of any series of preferred stock with which the warrants are being offered and the number of warrants being offered with each share of common stock or preferred stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on and after which the holder of the warrants can transfer them separately from the related common stock or series of preferred stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of shares of common stock or preferred stock that can be purchased if a holder exercises the warrant and the price at which such common stock or preferred stock may be purchased upon exercise, including, if applicable, any provisions for changes to or adjustments in the exercise price and in the securities or other property receivable upon exercise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of any rights to redeem or call, or accelerate the expiration of, the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which the right to exercise the warrants begins and the date on which that right expires;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of warrants outstanding, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of any material U.S. federal income tax considerations applicable to the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms, if any, on which we may accelerate the date by which the warrants must be exercised;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the warrants are issued pursuant to a warrant agreement with a warrant agent or issued directly by us; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrants for the purchase
of common stock or preferred stock will be in registered form only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If warrants for the purchase
of debt securities are offered, the prospectus supplement will describe the following terms, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the offering price and the aggregate number of warrants offered;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the currencies in which the warrants are being offered;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation, aggregate principal amount, currencies, denominations and terms of the series of debt securities that can be purchased if a holder exercises a warrant;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation and terms of any series of debt securities with which the warrants are being offered and the number of warrants offered with each such debt security;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on and after which the holder of the warrants can transfer them separately from the related series of debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the principal amount of the series of debt securities that can be purchased if a holder exercises a warrant and the price at which and currencies in which such principal amount may be purchased upon exercise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of any rights to redeem or call the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which the right to exercise the warrants begins and the date on which such right expires;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of warrants outstanding, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of any material U.S. federal income tax considerations applicable to the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms, if any, on which we may accelerate the date by which the warrants must be exercised;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the warrants are issued pursuant to a warrant agreement with a warrant agent or issued directly by us; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrants for the purchase
of debt securities will be in registered form only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A holder of warrant certificates
may exchange them for new certificates of different denominations, present them for registration of transfer and exercise them at the
corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Until any warrants
to purchase common stock or preferred stock are exercised, holders of the warrants will not have any rights of holders of the underlying
common stock or preferred stock, including any rights to receive dividends or to exercise any voting rights, except to the extent set
forth under &ldquo;Warrant Adjustments&rdquo; below. Until any warrants to purchase debt securities are exercised, the holder of the warrants
will not have any of the rights of holders of the debt securities that can be purchased upon exercise, including any rights to receive
payments of principal, premium or interest on the underlying debt securities or to enforce covenants in the applicable indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exercise of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each holder of a warrant is
entitled to purchase the number of shares of common stock or preferred stock or principal amount of debt securities, as the case may be,
at the exercise price described in the applicable prospectus supplements. After the close of business on the day when the right to exercise
terminates (or a later date if we extend the time for exercise), unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A holder of warrants may exercise
them by following the general procedure outlined below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delivering to us or to the warrant agent the payment required by the applicable prospectus supplements to purchase the underlying security;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">properly completing and signing the reverse side of the warrant certificate representing the warrants; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delivering the warrant certificate representing the warrants to us or to the warrant agent within five business days of receipt of payment of the exercise price.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the holder complies with
the procedures described above, the warrants will be considered to have been exercised when we receive or the warrant agent receives,
as applicable, payment of the exercise price, subject to the transfer books for the securities issuable upon exercise of the warrant not
being closed on such date. After the holder has completed those procedures and subject to the foregoing, we will, as soon as practicable,
issue and deliver to such holder the common stock, preferred stock or debt securities that such holder purchased upon exercise. If the
holder exercises fewer than all of the warrants represented by a warrant certificate, a new warrant certificate will be issued to such
holder for the unexercised amount of warrants. Holders of warrants will be required to pay any tax or governmental charge that may be
imposed in connection with transferring the underlying securities in connection with the exercise of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Amendments and Supplements to the Warrant Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may amend or supplement
a warrant agreement without the consent of the holders of the applicable warrants to cure ambiguities in the warrant agreement, to cure,
correct or supplement a defective provision in the warrant agreement, or to provide for other matters under the warrant agreement that
we and the warrant agent deem necessary or desirable, so long as, in each case, such amendments or supplements do not materially adversely
affect the interests of the holders of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrant Adjustments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the applicable prospectus
supplements state otherwise, the exercise price of, and the number of securities covered by, a common stock warrant or preferred stock
warrant will be adjusted proportionately if we subdivide or combine our common stock or preferred stock, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, unless the prospectus
supplements state otherwise, if we, without payment therefor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue capital stock or other securities convertible into or exchangeable for common stock or preferred stock, or any rights to subscribe for, purchase or otherwise acquire any of the foregoing, as a dividend or distribution to holders of our common stock or preferred stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pay any cash to holders of our common stock or preferred stock other than a cash dividend paid out of our current or retained earnings or other than in accordance with the terms of the preferred stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue any evidence of our indebtedness or rights to subscribe for or purchase our indebtedness to holders of our common stock or preferred stock; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue common stock or preferred stock or additional stock or other securities or property to holders of our common stock or preferred stock by way of spinoff, split-up, reclassification, combination of shares or similar corporate rearrangement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then the holders of common stock warrants and
preferred stock warrants, as applicable, will be entitled to receive upon exercise of the warrants, in addition to the securities otherwise
receivable upon exercise of the warrants and without paying any additional consideration, the amount of stock and other securities and
property such holders would have been entitled to receive had they held the common stock or preferred stock, as applicable, issuable under
the warrants on the dates on which holders of those securities received or became entitled to receive such additional stock and other
securities and property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as stated above, the
exercise price and number of securities covered by a common stock warrant or preferred stock warrant, and the amounts of other securities
or property to be received, if any, upon exercise of those warrants, will not be adjusted or provided for if we issue those securities
or any securities convertible into or exchangeable for those securities, or securities carrying the right to purchase those securities
or securities convertible into or exchangeable for those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of common stock warrants
and preferred stock warrants may have additional rights under the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain reclassifications, capital reorganizations or changes of the common stock or preferred stock, as applicable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain share exchanges, mergers, or similar transactions involving us and which result in changes of our common stock or preferred stock, as applicable; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain sales or dispositions to another entity of all or substantially all of our property and assets.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If one of the above transactions
occurs and holders of our common stock or preferred stock are entitled to receive stock, securities or other property with respect to
or in exchange for their securities, the holders of the common stock warrants and preferred stock warrants then outstanding, as applicable,
will be entitled to receive upon exercise of their warrants the kind and amount of shares of stock and other securities or property that
they would have received upon the applicable transaction if they had exercised their warrants immediately before the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_009"></A>DESCRIPTION OF OUR RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary, together with
the additional information we include in any applicable prospectus supplements, summarizes the material terms and provisions of the rights
that we may offer under this prospectus, which consist of rights to purchase our common stock, preferred stock and/or debt securities
in one or more series. Rights may be offered independently or together with our common stock, preferred stock, debt securities and/or
warrants offered by any prospectus supplement and may be attached to or separate from those securities. While the terms we have summarized
below will generally apply to any future rights we may offer pursuant to this prospectus, we will describe the particular terms of any
rights that we may offer in more detail in the applicable prospectus supplements. The terms of any rights we offer under a prospectus
supplement may differ from the terms we describe below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The applicable prospectus
supplements relating to any rights that we offer will include specific terms of any offering of rights for which this prospectus is being
delivered, including the following, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date for determining the persons entitled to participate in the rights distribution;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the price, if any, per right;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise price payable for each share of common stock, share of preferred stock or debt security upon the exercise of the rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of rights issued or to be issued to each holder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number and terms of the shares of common stock, shares of preferred stock or debt securities that may be purchased per each right;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which the rights are transferable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other terms of the rights, including the terms, procedures and limitations relating to the exchange and exercise of the rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the respective dates on which the holder&rsquo;s ability to exercise the rights will commence and will expire;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of rights outstanding, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of any material U.S. federal income tax considerations applicable to the rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which the rights may include an over-subscription privilege with respect to unsubscribed securities; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if applicable, the material terms of any standby underwriting or purchase arrangement entered into by us in connection with the offering of such rights.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The description in the applicable
prospectus supplements of any rights that we may offer will not necessarily be complete and will be qualified in its entirety by reference
to the applicable rights agreement and/or rights certificate, which will be filed with the SEC in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_010"></A>DESCRIPTION OF OUR UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary, together with
the additional information we include in any applicable prospectus supplements, summarizes the material terms and provisions of the units
that we may offer under this prospectus, which may consist of one or more shares of our common stock, shares of our preferred stock, debt
securities, warrants, rights or any combination of such securities. While the terms we have summarized below will generally apply to any
future units we may offer pursuant to this prospectus, we will describe the particular terms of any units that we may offer in more detail
in the applicable prospectus supplements. The terms of any units we offer under a prospectus supplement may differ from the terms we describe
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The applicable prospectus
supplements relating to any units that we offer will include specific terms of any offering of units for which this prospectus is being
delivered, including the following, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether we will apply to have the units traded on a securities exchange or securities quotation system;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a discussion of any material U.S. federal income tax considerations applicable to the units; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">how, for U.S. federal income tax purposes, the purchase price paid for the units is to be allocated among the component securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The description in the applicable
prospectus supplements of any units that we may offer will not necessarily be complete and will be qualified in its entirety by reference
to the applicable unit agreement, which will be filed with the SEC in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_011"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales by Us</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
being offered hereby in one or more of the following ways from time to time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to or through underwriters;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the over-the-counter market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in transactions other than on these exchanges or systems or in the over-the-counter market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in &ldquo;at the market offerings,&rdquo; within the meaning of Rule 415(a)(4) of the Securities Act, to or through market makers or into an existing market for the securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exchange distribution in accordance with the rules of the applicable exchange;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately negotiated transactions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an accelerated securities repurchase program;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a combination of any of these methods of sale; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other method permitted pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will identify the specific
plan of distribution, including any underwriters, dealers, agents or other purchasers, persons or entities, and any applicable compensation,
in a prospectus supplement, in an amendment to the registration statement of which this prospectus is a part, or in other filings we make
with the SEC under the Exchange Act, which are incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sale through Underwriters or Brokers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If underwriters are used in
the sale, the underwriters may resell the securities from time to time in one or more transactions, including negotiated transactions,
at a fixed public offering price or at varying prices determined at the time of sale. Underwriters may offer securities to the public
either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters.
Unless we inform you otherwise in the applicable prospectus supplement, the obligations of the underwriters to purchase the securities
will be subject to certain conditions, and the underwriters will be obligated to purchase all of the offered securities if they purchase
any of them. The underwriters may change from time to time any initial public offering price and any discounts or concessions allowed
or re-allowed or paid to brokers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will describe the name
or names of any underwriters, brokers or agents and the purchase price of the securities in a prospectus supplement relating to the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the sale
of the securities, underwriters may receive compensation from us or from purchasers of the securities, for whom they may act as agents,
in the form of discounts, concessions or commissions. Underwriters may sell the securities to or through brokers, and these brokers may
receive compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers
for whom they may act as agents, which is not expected to exceed that customary in the types of transactions involved. Underwriters, brokers
and agents that participate in the distribution of the securities may be deemed to be underwriters, and any discounts or commissions they
receive from us, and any profit on the resale of the securities they realize may be deemed to be underwriting discounts and commissions,
under the Securities Act. The prospectus supplement will identify any underwriter or agent and will describe any compensation they receive
from us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Underwriters could make sales
in privately negotiated transactions and/or any other method permitted by law, including sales deemed to be an &ldquo;at the market&rdquo;
offering, sales made directly on the NYSE American, the existing trading market for our shares of common stock, or sales made to or through
a market maker other than on the NYSE American. The name of any such underwriter or agent involved in the offer and sale of our securities,
the amounts underwritten, and the nature of its obligations to take our securities will be described in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise specified
in the prospectus supplement, each series of the securities will be a new issue with no established trading market, other than our shares
of common stock, which are currently traded on the NYSE American. It is possible that one or more underwriters may make a market in a
series of the securities, but underwriters will not be obligated to do so and may discontinue any market making at any time without notice.
Therefore, we can give no assurance about the liquidity of the trading market for any of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under agreements we may enter
into, we may indemnify underwriters, brokers, and agents who participate in the distribution of the securities against certain liabilities,
including liabilities under the Securities Act, or contribute with respect to payments that the underwriters, brokers or agents may be
required to make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any compensation we pay underwriters
or brokers will be subject to the guidelines of the Financial Industry Regulatory Authority, Inc. We will disclose the compensation in
any applicable prospectus supplement or pricing supplement, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To facilitate the offering
of securities, certain persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect
the price of the securities. This may include over-allotments or short sales of the securities, which involve the sale by persons participating
in the offering of more securities than we sold to them. In these circumstances, these persons would cover such over-allotments or short
positions by making purchases in the open market or by exercising their over-allotment option, if any. In addition, these persons may
stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids,
whereby selling concessions allowed to brokers participating in the offering may be reclaimed if securities sold by them are repurchased
in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the
securities at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
engage in transactions with these underwriters, brokers, and agents in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Direct Sales and Sales through Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
directly. In this case, no underwriters or agents would be involved. We also may sell the securities through agents designated by us from
time to time. In the applicable prospectus supplement, we will name any agent involved in the offer or sale of the offered securities,
and we will describe any commissions payable to the agent. Unless we inform you otherwise in the applicable prospectus supplement, any
agent will agree to use its reasonable best efforts to solicit purchases for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
directly to institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect
to any sale of those securities. We will describe the terms of any sales of these securities in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales by Selling Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders may
resell or redistribute shares of our common stock from time to time on any stock exchange or automated interdealer quotation system on
which the shares of our common stock are listed, in the over-the-counter market, in privately negotiated transactions, or in any other
legal manner, at fixed prices that may be changed, at market prices prevailing at the time of sale, at prices related to prevailing market
prices or at negotiated prices. Persons who are pledgees, donees, transferees, or other successors in interest of any of the named selling
stockholders (including but not limited to persons who receive shares of our common stock from a named selling stockholder as a gift,
partnership distribution or other non-sale-related transfer after the date of this prospectus) may also use this prospectus and are included
when we refer to &ldquo;selling stockholders&rdquo; in this prospectus. The selling stockholders may sell the shares of our common stock
by one or more of the following methods, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block trades (which may include cross trades) in which the broker or dealer so engaged will attempt to sell the shares of our common stock as agent but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by a broker or dealer as principal and resale by the broker or dealer for its own account;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exchange distribution or secondary distribution in accordance with the rules of any stock exchange on which the shares of our common stock may be listed;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage transactions and transactions in which the broker solicits purchases;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an offering at other than a fixed price on or through the facilities of any stock exchange on which the shares of our common stock are listed or to or through a market maker other than on that stock exchange;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately negotiated transactions, directly or through agents;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the writing of options on the shares of our common stock, whether or the options are listed on an options exchange;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the distribution of the shares of our common stock by any selling stockholders to its partners, members or stockholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one or more underwritten offerings;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">agreements between a broker or dealer and any selling stockholder to sell a specified number of the shares of our common stock at a stipulated price per share; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any combination of any of these methods of sale or distribution, or any other method permitted by applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders may
also transfer the shares of our common stock by gift.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders may
engage brokers and dealers, and any brokers or dealers may arrange for other brokers or dealers to participate in effecting sales of shares
of our common stock. These brokers, dealers or underwriters may act as principals, or as an agent of a selling stockholder. Broker-dealers
may agree with a selling stockholder to sell a specified number of shares of our common stock at a stipulated price per share. If the
broker-dealer is unable to sell shares of our common stock acting as agent for a selling stockholder, it may purchase as principal any
unsold shares of our common stock at the stipulated price. Broker-dealers who acquire shares of our common stock as principals may thereafter
resell the shares of our common stock from time to time in transactions in any stock exchange or automated interdealer quotation system
on which shares of our common stock are then listed, at prices and on terms then prevailing at the time of sale, at prices related to
the then-current market price or in negotiated transactions. Broker-dealers may use block transactions and sales to and through broker-dealers,
including transactions of the nature described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, one or
more of the selling stockholders may pledge, hypothecate or grant a security interest in some or all of the shares of our common stock
owned by them. The pledgees, secured parties or persons to whom the shares of our common stock have been hypothecated will, upon foreclosure
in the event of default, be deemed to be selling stockholders. The number of a selling stockholder&rsquo;s shares of our common stock
offered under this prospectus will decrease as and when it takes such actions. The plan of distribution for that selling stockholder&rsquo;s
shares of our common stock will otherwise remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders and
any underwriters, brokers, dealers or agents that participate in the distribution of the shares of our common stock may be deemed to be
&ldquo;underwriters&rdquo; within the meaning of the Securities Act, and any discounts, concessions, commissions or fees received by them
and any profit on the resale of the shares of our common stock sold by them may be deemed to be underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A selling stockholder may
enter into option or other transactions with broker-dealers that involve the delivery of the shares of our common stock offered hereby
to the broker-dealers, who may then resell or otherwise transfer those shares of common stock. A selling stockholder may also loan or
pledge the shares of our common stock offered hereby to a broker-dealer and the broker-dealer may sell the shares of our common stock
offered hereby so loaned or upon a default may sell or otherwise transfer the pledged shares of our common stock offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholders and
other persons participating in the sale or distribution of the shares of our common stock will be subject to applicable provisions of
the Exchange Act and the related rules and regulations adopted by the SEC, including Regulation M. This regulation may limit the timing
of purchases and sales of any of the shares of our common stock by the selling stockholders and any other person. The anti-manipulation
rules under the Exchange Act may apply to sales of shares of our common stock in the market and to the activities of the selling stockholders
and their affiliates. Furthermore, Regulation M may restrict the ability of any person engaged in the distribution of the shares of our
common stock to engage in market-making activities with respect to the particular shares of our common stock being distributed for a period
of up to five business days before the distribution. These restrictions may affect the marketability of the shares of our common stock
and the ability of any person or entity to engage in market-making activities with respect to the shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may agree to indemnify
the selling stockholders and their respective officers, directors, employees and agents, and any underwriter or other person who participates
in the offering of the shares of our common stock, against specified liabilities, including liabilities under the federal securities laws
or to contribute to payments the underwriters may be required to make in respect of those liabilities. The selling stockholders may agree
to indemnify us, the other selling stockholders and any underwriter or other person who participates in the offering of the shares of
our common stock, against specified liabilities arising from information provided by the selling stockholders for use in this prospectus
or any accompanying prospectus supplement, including liabilities under the federal securities laws. In each case, indemnification may
include each person who is an affiliate of or controls one of these specified indemnified persons within the meaning of the federal securities
laws or is required to contribute to payments the underwriters may be required to make in respect of those liabilities. The selling stockholders
may agree to indemnify any brokers, dealers or agents who participate in transactions involving sales of the shares of our common stock
against specified liabilities arising under the federal securities laws in connection with the offering and sale of the shares of our
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not receive any proceeds
from sales of any shares of our common stock by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you that
the selling stockholders will sell all or any portion of the shares of common stock offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will supply the selling
stockholders and any stock exchange upon which the shares of our common stock are listed with reasonable quantities of copies of this
prospectus. To the extent required by Rule 424 under the Securities Act in connection with any resale or redistribution by a selling stockholder,
we will file a prospectus supplement setting forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate number of shares of common stock to be sold;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The purchase price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The public offering price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If applicable, the names of any underwriter, agent or broker-dealer; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any applicable commissions, discounts, concessions, fees or other items constituting compensation to underwriters, agents or broker-dealers with respect to the particular transaction (which may exceed customary commissions or compensation).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a selling stockholder notifies
us that a material arrangement has been entered into with a broker-dealer for the sale of shares of our common stock through a block trade,
special offering, exchange, distribution or secondary distribution or a purchase by a broker or dealer, the prospectus supplement will
include any other facts that are material to the transaction. If applicable, this may include a statement to the effect that the participating
broker-dealers did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_012"></A>SELLING STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
the registration statement of which this prospectus forms a part is used by selling stockholders for the resale of any shares of our common
stock registered hereunder, information about such selling stockholders, their beneficial ownership of our securities and their relationship
with us will be set forth in a prospectus supplement, in a post-effective amendment, or in filings we make with the SEC under the Exchange
Act that are incorporated by reference herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_013"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated
in the applicable prospectus supplement, the validity of the securities being offered by this prospectus will be passed upon for us by
Olshan Frome Wolosky LLP, New York, New York. Additional legal matters may be passed upon for us or any underwriters, dealers or agents
by counsel that we will name in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_014"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements of
OS Therapies Incorporated incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 31,
2024 have been so incorporated in reliance on the report, which contains an explanatory paragraph regarding the Company&rsquo;s ability
to continue as a going concern, of MaloneBailey, LLP, an independent registered public accounting firm, given on the authority of said
firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_015"></A>Where
You Can Find More Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">We
have filed with the SEC a registration statement on Form S-3 under the Securities Act relating to the offering of these securities. The
registration statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus
does not contain all of the information set forth in the registration statement. We encourage you to carefully read the registration statement
and the exhibits and schedules to the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the reporting
requirements of the Exchange Act and file annual, quarterly and current reports, proxy statements and other information with the SEC.
The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding issuers
that file electronically with the SEC, including us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
registration statement and the documents referred to below under &ldquo;Incorporation of Certain Information by Reference&rdquo; are also
available on our Internet website www.ostherapies.com. We have not incorporated by reference into this prospectus the information on our
website, and you should not consider it to be a part of this prospectus</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="b_016"></A><FONT STYLE="text-transform: uppercase"><B>Incorporation
of CERTAIN INFORMATION by Reference</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC and applicable law
allows us to &ldquo;incorporate by reference&rdquo; the information from other documents we file with the SEC, which means that we can
disclose important information to you by referring you to those documents instead of having to repeat the information in this prospectus.
The information incorporated by reference is considered to be part of this prospectus, and later information that we file with the SEC
will automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings
(including those made after the date of the initial filing of the registration statement of which this prospectus is a part and prior
to the effectiveness of such registration statement) we will make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange
Act until the termination of the registration statement of which this prospectus is a part (other than, in each case, documents or information
deemed to have been furnished and not filed in accordance with SEC rules):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Annual Report on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025026238/ea0235597-10k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended December 31, 2024, filed with the SEC on March 31, 2025;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025 and June 30, 2025, filed with the SEC on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025044336/ea0242061-10q_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 15, 2025</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025077916/ea0252948-10q_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 18, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Current Reports on Form 8-K (only to the extent &ldquo;filed&rdquo; and not &ldquo;furnished&rdquo;) filed with the SEC on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025000844/ea0226635-8k_osthera.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 3, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025003460/ea0227697-8k_osthera.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 14, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025003886/ea0227757-8k_osthera.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 15, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025007705/ea0229055-8k_osthera.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 29, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025027522/ea0236724-8k_ostherapies.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025030375/ea0237768-8k_ostherapies.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 9, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025032071/ea0238051-8k_ostherapies.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 15, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025056911/ea0246590-8k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 24, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025058603/ea0247272-8k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 27, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025063479/ea0248754-8k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 14, 2025</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025077431/ea0253338-8k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 15, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of our registered securities contained in </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1795091/000121390025026238/ea023559701ex4-9_ostherap.htm">Exhibit 4.9</A></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to our Annual Report on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1795091/000121390025026238/ea0235597-10k_ostherap.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended December 31, 2024, filed with the SEC on March 31, 2025.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statement contained in
this prospectus, or in a document all or a portion of which is incorporated by reference, shall be modified or superseded for purposes
of this prospectus to the extent that a statement contained in this prospectus, any applicable prospectus supplement and any related free
writing prospectus or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or
superseded shall not, except as so modified or superseded, constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon request, we will provide,
without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered a copy of the documents
incorporated by reference into this prospectus. You may request a copy of these filings, and any exhibits we have specifically incorporated
by reference as an exhibit in this prospectus, at no cost by writing or telephoning us at the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OS Therapies Incorporated</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">115 Pullman Crossing Road, Suite 103</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Grasonville, Maryland 21638</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attention: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(410) 297-7793</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional information about
us is available at our website located at www.ostherapies.com. Information contained on, or accessible through, our website is not a part
of, and is not incorporated by reference into, this prospectus or any accompanying prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>500,000 Shares of Common Stock</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea029753101_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OS Therapies Incorporated </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Prospectus
Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus Supplement dated August 6, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ea029753101_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029753101_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !  9$# 2(  A$! Q$!_\0
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MU:E*<[R:5THKI!\^LMVE9)=]/D\LP^;XK&YIA'FLN6,HI:7MKMO[M[/[_O\
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M2EO_ !,FG^/M#T37/$+)K@<,I/FR!3D,@("E2J[?W/\ ^&VOV.NI_:H_9WW
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MGC?XDO>V;Z;'H6L_\(=I>N^-A+I9S_8\5K<?VSYD",6M5C&0S 1G^6'XW?\
M!>C]L']HCXO:O\'_ /@FQ\$1K-E:7E_;>'?$;^#=8^(_Q(\66,"@?\)!%X<R
MWA7PQX?+9?=XJ)<?*"[;%-?U$?M8?#W7/BO^S'^T!\,O"4PM?%7CKX0?$3PO
MX<8'Y1JWB'PAK>CZ1@D\[YI%)'KGM7\47_!%W]OWX0?\$[_B;\;_ (<?M.^%
MM8\)'QW>^%='O?&MOX:;4O$G@;Q1X#.O:)KFA^.-%3/BB+P^7UI2LH63R_[
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MC%/57L^CZ'1E]#$_6KX;->>.\H-J3MU2U?X+2U]3Z.W?[+?E13J*^?\ W/\
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ML./_ *W\\XK_ *4\IRS"<6<&Y)Q1\-7/*-.49;.,IT:4]5[MTW)73CKY7/\
M ^IXI\1^$'BEQ;P;)RSO(LDXIFK2DWRTY5)?"Y-\JC![K1V3>]E_IY:-\$_@
MWH=_;ZQHWPO^'>F:C:DW%I?V'A#1;"^M,C[XFCM4G0X/+*4"E3P#R/6AR!_"
M ,9!_KVZ=#GK]#7\P/\ P0Z_X*-?'WXT:W<_LY?'R[/C6+2_#M[>_#+XF:F5
MC\3ZI'H# :WH^OO@MXA:!9&D7Q,"#(5$+9! 7^G]<,@QQNY_4?A^'Y5^>9GA
M,5@L6\-BKNUTFVWITM=M:I)Z']Q<%\993QMDT<YRCX)/EE&R]V=DW%M:.S;V
MZ+O=#Z#R"/6BCI7"?8=/EM\C^;O_ (*%17GP@_;N\#_%J[M%?1IS\+O&5GM(
M)O?^$%UA7UI6 /RMY>C(<'YBI5NA!K^A#PMXATGQ7X?TG7]!O;?4M(UK2[+5
M-.N[4[OM>GS(DR2J3U!21< 8_P!85QG<:^6OVQ_V3=#_ &H_A\NE+=0Z'XV\
M,LVI>"/$&T[;'5%1S_9NJB.$M-H<V$$T(.0V'50<B;\<?!?Q6_;H_80DN?!6
MN> -0\2^";:Y,>C:=J>D:QXB\/(K$DIH6O\ AWYE&<$HQVD@;EXQ7WDJ&$XI
MR?*<'A9QCG&2J:<)2454B^:S3E)>\D[]4E*2>EF?BGUG&<"\69QC,7E<YY)G
MSC)U*:<W&46VVU%2MO/1V;5I+JC^E!5CC3:JE(8R79GQDD'..WN !QUSFOYT
M_P#@J'XPL_BU^TCX ^%'A%AJNM>'=,T_PW>):'<?^$D\<:V(K?1V.3\[VT4#
MN#DJS,IY4U:U_P#X*,?MC_%NP'A'X;?"5O#^L:CNL_[5\+>$?&7B/Q",C);1
MH==V0.1R0\D;,IR59>*^A?V&?V!O%OAGQO#^T!^T"S-XRM[N76?#7A2XO#J.
MI6>JZQCS/%WC.4[5D\4'++B-F\HI(7VM'L.N7X%\+REFV;3IJHJ=14J4:L)3
ME)QE'F?+*3M=Q5U%J-W=MVB8<09Q/CJ66</Y!EE5Y2ZL)UZ\XSIQBH24K)24
M;6:E+5W;226K9^NWAVW@\*>$=&LKVXBABT#P]IFGW5U.<*(](TM(WD<YQA0G
MF$D_=!(!)!'AWBCX'?LR?M,:/;^+-;\(^"OB/9:E&K6?BG21')>7: D%UUS0
MGAN752NTYE(3(&%RN-G]IOX+_P#"_P#X.>,/AG!XAO\ PG>ZW:;M*U>RGD39
M?Z6TC1KJR*CF?13(L:S1@HQ,@D WE(Y/PD\#>./VT_V -0OO"5[X!U+Q)X+E
MO'NTT^?2-9\1>#+DL%WZMH>O>'\GP\"50R0R*R,R)YD;%!CQ<FP#S-5<5@,S
M]EFKJ2<*?.Z:E%RE/22G%7;G9Z:.ZEI*Y])Q5FRR+$Y3@LVR5YWDWLX1=2-+
MVLJ4U",$]82MR\MFDT[;/3E/L_XR_P#!)/X6ZEI&K:G\'O%'B+PIXH@MI+RS
MTK7[W_A(O#-Y?J"5TPK)M.AQL=B%X?, :1#@H'=?./\ @DU\9_&C>*_'/[/W
MB6^N=0T'2M#?Q%X:@N+W^T9O#^I:/K0T#7M$A?/RZ%O$9B."0P 7!8D<3XA_
MX*8?M2_$O19O!WPY^![:-X@UNT:T_M;2M'\8>(=1LW<89]'2)(XW<]BR'!.X
M#/-?3/\ P3;_ &/_ !M\&Y?$GQA^+%K_ &%XK\4:5!I&D^%[@C^T-%TR29=9
MU74M<<*^?$%S,55R@($:NK,H=6KZ#$RQ>$X?S;!\1SIRG)Q^KING*JJB3O)2
MC>3C>S=KN*YKS2E%'QF7K+<3QQE6+X$RNI3I7?\ K1S*K3IQB[N*49VCS)65
MHI)M;;L_88<@4445^<'] ]'I;3]#^&W_ (+9?\IF?@/_ -VP?^K/K^XN+_4I
M]#^@;'\A^5?Q"?\ !:;3-5N_^"R7P&F@TK7+F#'[, -W:Z/JVI:;_P E/.0W
ME_(&!R#MX!XK^WR+_5Q_C_[-7T&<M?4<F5T[8=IV=[:1\W;YI'S.4)K-<U=F
MES1L[-=7L[+\#\)_^#B;_E&_XJ_[*U\*_P#T_P M?B/_ ,$Z?^"%?PR_;G_9
M<\'_ +17B/X^?$#P!J_BC5O%&C7?A7P_X/\ !VIZ59'0M8DT/:!KRNY8"(D_
M+G!&W<Q"G]P?^#A^SO;W_@G#XJALK"XU&X/Q1^%Q%K:V?]H.0-=D!RAP0!D?
M,1R3C&,5T7_! &&YM/\ @FE\*+>\L[FSN/\ A+?B<3;W5G]@=1_PF5T 3%M/
M .,-U8Y7J!75ALQQ>#X>:P<K.6(;:M%Z-IVM).RERI72OVM<X,3EN&Q?$#>+
MBVE#1IR5]']I:==FSX"_XA9?@KM+']K'XO#&>/\ A /ASD@'D_ZFOQDOOV4]
M$_8D_P""R7P%_9N\/>,-:\>Z3X.^-?P'O;7Q5X@M=&T_4KUO'.BZ!KK*-%\/
M@;MK KN &>H ZU_HC$$_.>A5L@?0CIWZ?SK^(#]NK3=7F_X.(?AY?1:5JEQ8
M#XI_LF9NK?2-6;3P1X,T 8=DRC-QAMO&<]Q7;PYG>-Q%7,HXRHG"6'J-IJ";
MFG%*2E&,>CDK)V:LTNIAG62X;#?V8\&I+EJI6O)Z7O=J[MKW_P S^S'XN<_"
M/XI9 X^'GC7'_A/ZR:_SW?\ @E=_P3>\)_\ !2'XE_&;P/XL^)OB3X70?#/P
M[IGB2QN_#OAS1?$?V\ZYJSZ,?^1AXP%C<D]\5_H1_%P8^$?Q3_[)YXU_],&L
MC^E?YUO_  3T_;Y^+7_!.CQY\5O&/@?X+VWQ'NOB;I.F>&[FV\5V7C#3CIK:
M'J[ZWN']@JRYVNP'RGJ0>"0<^'7C/J6;K R4:C5.UW%>]Y*;Y=N;=/47$2PO
MUS*7C(R<5S7LI.R\W%-I_-'[V?\ $+/\(<_\G:?%+'_9._ _\O-_K7] _P"Q
MM^S9I/['7[-GPJ_9MT7Q1JGC72/A/HFHZ+8>*=7LM)TO4];BN-:UG76>32-#
M!@C='UAP84W,=BL<N^!_+I_Q$P_M3?\ 1GO@/_P+^)'_ ,37[C?\$EO^"A7Q
M%_X*%?#SXP>./B7\*=*^%&H_#SXBZ9X-TC3=*;6BFM:7JW@[0_$2:NW]ND3'
M<;AE14# 1I@X"@/P9UA\_P#JR>;--=+2I2U=[6Y-=4UJ_P #T<GQ&0O%6P2E
MS6LN93WZZRTWVM^9^5/_  =-[?\ A"/V./,Q@^+_ (Q'\#H?@'\/3K7R?\%I
M?^#BK_A4'PO/PAM_%/\ PJ?_ (0?PG_PK@V__#/_ /R(XT>/_A'L_P#"19\3
M[_\ A'O*\O/S;O+V\[:^M?\ @Z.TZ^O/ G[(2V6F:IJ;+XE^,6Y=,L]3U-U!
MT3P#MR(. K8RI;YB0<<5_0C^PO;-%^QM^R_%/#]GE'P&^%P*8Z8\%:)DCIUW
M+QSG;[<]W]H+"\-Y7'EISM4JMJ:323E)MVM)];;:IO8\Y9;+$\19K).4;I<K
M5X]%:STVLK:Z;G\+WA@_MU?\%4_VH-*_8_\ VF/VG+CPCXG\*:IXG^V^$?BH
M(O"^FZ%XD\.@C6]#T/P3H7AV*/7_ (@QITWR*B*#R *_NE_8\_94^&_[%GP!
M\%_ ?X8+<7&@^%[5[S4]<U)D;5_%GB35V636_%FM,6VFZOF4,Z(0@C"1$%X?
M.D_G:_X+R?L.>,O 'C/PM_P4J_9A@U31/'7@[5_#3?%X^%K)UU2PU70'9?!7
MQC4:(L4S+"X'A?QE))$GG6LEO*K3,TDA_;C_ ()J?MNZ5^W-^S;H7Q'O-.E\
M,_$[PTJ>%OC!X4N-/_LXZ)XW7;YFJZ4FT*_A[Q3&A\1VTF_A9C&8L0[YL,YQ
M+QF599B,'RQRG6,Z47%.%5WYN91Y9.[E=.4%I:5FY-KHR7#_ %7-,SP^+O/-
M6E*$WS-2A:\>63NEHDM)=UTU_.K_ (.+/VMU^#_[*6C_ +.GAG4C9>-OVDM8
M;3M8CM+A(M1L?AEX>/\ :^N.J[F8?\)5K\6A^%HVPJR6LOB'EO+!7\RO^"6O
M_!7G]AO]@']EW3?A1X@\&?&S6?BEK?B+4_&7Q2U_0?!WA&31K_Q-X@D4Z5HN
MCZLOBJ*.70/"WA9-#B@=QNMB\CKO61XV\\^+-EK?_!6[_@M3HW@T:3K6H_ 7
MX?\ BW_A"UN;JSU9=*3X,_"8?V_XXU9>(T5/BKXBPB$A<+KWA?<>IK^L<?\
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M^V+?^%/#6HVVH>'_ ($^!/#/PG^T69_XEH\5:,[>(M?)P>'+:\?##@$@-H!
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MW6M^!R/_  A?A#_H5?#W_@ETKW_Z8>X^F/\ 9Y/^$+\'Y_Y%7P]_X)=*]_\
MIA[C\O\ 9KJOW?\ G=1^[_SNH>+D]ZD_G.7ZS.=8/#+:E'_P&'_R!7A@B@CA
MAAB\B"W^ZN   ,\ 9).2>3FLG7/#?A_Q)8?V5X@T31]:L6 )L]4TJ+4;'CTC
MG1HA]<@UT5%";3NFT^Z;3^]-/\3H:35FDUV:37W--?@>3:1\&O@_H%ZVI^'?
MA1\.]!OF Q?Z3X&T+3-0&.N&@T)91]00?7J:]7"*.@ J/>WK^@_PHWMZ_H/\
A*'*3WE)^K;_-LS5&FM5%)]U&*?X11-129'J/S%%(U/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea029753101_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029753101_img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $[ G # 2(  A$! Q$!_\0
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MW6CZ/;7^L:MJ5LFF:9I[:?8Q26UR5@ /L_0/VX/V=_@?^SA^S;XZ_:H_;(^
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M,=6>)<#=J]_H U9Y-J^8]\SE?F!/AVD:7I/AS_@OMXNN-#L;#2+KQ[_P2_\
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M*;7U;&.S:NL/-IVNKI]4[73ZZ'[26O[)W[-UCX0\-^ +3X-^"+?P9X/^*?\
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M+7,EM#>+"T^9"A<[C^7*_&K_ (.(S][]B[]C 9]/C\Y_'.[W_P .@J=/C/\
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MRYZT8RC3Y9T)2:A&7-.HO=5K6E?3ZFM?^#IW]H&X95/[(_P=5R =H^)_C(L
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M!7%.?9EP!@,WQV85,1F-7-\?AIXF=.BI2HT:G+3@XPI0@E!:+W%+NV?K<?\
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MTVM(W=N5WL]M#Z?M/^#N#]HZYVY_8S^"B9QR/BMXYXR0._A+U/\ GH>FM/\
M@["_:%N" _[('P7C+8R/^%J>-0>?NYSX4!&XY"^IX[&O$[G_ ((:?LNZ9?\
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MH3J5'>%ESRG)M))*[LDK6_K^'_!X+^TJ2,_L4_ [KV^+?CS/_J(_G[5L6?\
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MD,OQ7\<.#SC@_P#") 'G'3KC!KPCX1?#O]@7P'_P3I_88U[]HSP'^R_IU_\
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M/2E9V:ENU925[Q9]5VG_  =8?M#704M^R!\&UW=0/BCXT/\ /PGZ_6NIM/\
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M ,R](W_!SA\>@K$?LJ?"<D G_DI7C#L,_P#0KU_,G S-!"S'<S11LS8V[F*
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M="T:XO\ QA'JWA;Q/\);CQ)I[Z/$/M"W>APZ9J$FIQ8W6J65RSX,9K^#E_\
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MX]UGP$;S69;B2[M?^$#U":X\,_V5$URZV.E?V=]AL8TBCMH(TB0"]XY_:_\
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MK?3ZG!JMG:>/[?58=4N[86%WJBWD>IBY74;NPQ876H&0WEQ9*EK-,\")&O\
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M2SJM@N',=F%3,Z%/+Z=.OFN34H_5O:RG+$N=.H_8U(W7[F2J76TT]3^ U?\
M@E[_ ,%&')"?L3_M&L5Z@?#C5R1VYPO//M6AI?\ P34_X*7Z+>&YT3]C[]J3
M1+]H+BS>ZT7P7XFTF^:SNXC%>6;W.G36UPUI=P,\-W:M(8+F%FBGCDC8J?\
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MKH]_8^$=/CM;/PO=:EITGB37=<\.V-NMU8W.K/;?4_@3]GV+P5\,?&_C/Q=
MDWBNX\!^*I-/L9 KIH$4N@7X)XRKZC*C$2RCY;=6,,629)&\1^"WA7]H+XA_
ML\?\$[OA_P"#4TK0/V?-3_9_^!WB;XT_$71_%5[H/Q.TR+P7X#\-:WI_P[T/
M3X(S]NT#XI:E'I&C>(M5LKRQO-(\.6GB*S832:O93VG_ $6_1"K>-5?P$X6J
M>.M.C3XL_<K NK[59Y4X>6"I_P!DU>)X37)#.Y4.5UU!^U=+V,L8HXQUD?P]
MXD1X4AQMF$>#Y5'E:A4]HERO!K&>W?UF.723YI8)5+^R<O=3YU1;HJFSZ_\
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M_-#XC_L)?MH?$;XL_&KXNW7B*WT+7->M].T?P)HGAKX^>(-,\':K\*]3O?#
M\2_!?6M.MOAG:WWA[[!H^E:O8Z?XXT>X19I=6N+C_A'O,FS'R7@/]JW]OG]G
M>#Q%9?$KPQJOC[2[3X2_\+WO].^/FH^&[3XG>'?!WA71-%\+>,9K:7X2QW^A
MV4'B3XK:L+CPUI'B&YO;[3/!]GJ%UJ%S9S1&W37/_!5;]HF]UKX:^%- \%?
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MTN=LL/\ 28;Q;I9IAH1J1@L&GA,CF\-)->T=9^TC]94DI**M1Y&UK*QY!/\
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M:[H<EWX$\06VEZ[:2G1-!UD->:AI5O-:<6S[/M**_P!WE5/55/U /\Z4  8
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MWSR?:M&+_@K7\<Y.O@'X<#KT.N_R-U]>_0>M<%3C[Z \;\W"V,?>V5<0^?\
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MX=  _P"%C:]^.DZ8/ZG^9J5?V ?#RX_XN+KYQC_F%:9V_#^>:_0?GU_SQ_\
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M4M[2WAA4L2Q5,L3R: /E32?V#/V8M"_:DU']L?1_ ,VF?';4])T_1;K7M/\
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M'I.@7?P]TFVUOP[-KD#Z#H4EWKNB^*]3M8+GQ(WA>#2(U9OW%H _,3_@LO\
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M3M/^",W[+49ROB+XK]NOB/1^W3_F7O\ .!5M/^".?[,"=/$/Q4Y]?$6D?_*
M>G^<BOS-A_X+*?M82<-H_P )N@/_ "+&K\9_[F'IR?R-:<7_  6%_:KD&3I'
MPIZ9R/#.K8[<\^(#ZUYU7Q0^A5&_M/#YR[_\8OB&O_5M8WCPOXT/2/$,5_W5
M*?\ \R'Z5)_P1_\ V9(_N^(/BC[Y\0Z2?RQH/U]>M6D_X)%?LU)TU_XG>O/B
M#2O_ )1^Q_/Z5^;\/_!7K]J:3&[2?A7_ .$UJWOZ:^?3M6G%_P %;_VH7/S:
M5\+<>WAS5@.WKKN>_P!*\ZKXK?0=5_:>'3??_C%<0_RSC?R.B/"OC:_AXC2_
M[JU-?^Z=^_0_1A/^"2W[-\? U[XEGC'.OZ5[>FB>Q_,>V;2?\$HOV=(^FN_$
MHX]=>TL^OIH@K\\8O^"L?[3D@^;2OAB..WAW5/;_ *CA]:TH?^"JW[2\A^;3
M/AF![>'=5]_^HX/Y?R!KSJOBU]!%7Y_#>3[_ /&)XA_^]G_@G1#A+QTE\/$B
M_P##Q!?^Z9TF@?L>?#*__P""C7Q"_9-EU#Q2OPX\*_L@?#OX[Z;?IJ%HOB5_
M&'BKXL^-/!&I6UU?&Q-K+HD>D>'K&:VM4LDN$O9)Y6G>-EB7[K3_ ()<?L^I
M]W7/B)^.MZ;[_P#4']_:OR'TK]L#XIV/[37B/]K""R\)GXF^*O@OX9^!&I6;
MZ9>MX83P9X5\7ZUXVTVYM=/_ +1%W%K<FL^(=0%U>/?20268AA2UC:,N_P!'
M1?\ !4#]HR0C=IGPY&<$XT#5 .GMK9]/\]:YL;XP_0 ;I.'AC))4*4:G_&'X
MGWJL(M59W>=:J4M;K1[)1V'0X/\ 'U<ZEQ1=NK4<&LYIZ4Y-.$?]QW2NM=?-
MGWJG_!,7X!I]W7/B#^.LZ<?7_J$>]6H_^":'P(CQC6O'QQZZQI_MW&E#TKX5
MA_X*:?M#.?FTSX=_4:'JGO\ ]1K/;_/6M&'_ (*4?M!28!T[X?#.,D:)J?MD
M\ZP>N?3J>@Q7D5?&7]GRK^T\,&^__&'8A_\ O;.R/!WT@'\/%#_\/<%_[I'W
M*G_!-WX&Q_=UGQYQTSJ]@<=/^H6/3_\ 75A?^"<_P248&L^.>W75;'M_W#17
MQ-#_ ,%&_C](1NL/ '..FBZD!V]=6)[UHI_P40^/+];'P&.G31M0YS]=5/''
MZUYU3QH_9V1O[3PLD^]^#,2__>Y^IO'@OZ0S^'BE_P#A]IK_ -T;GV</^"=W
MP5'36?&^?^PI8_\ RM_SQZ5,O_!/3X+KTUCQOTQ_R%+'_P"5M?&R_P#!0GXZ
MD@-9>!3GKG1=0XXSVU4<?@:M1_\ !03XYMULO W0]-'U#UXX.J?U[_B.2?C7
M^SE5^;PJ;O\ ]45BMO\ P^H?^I?TAKM?ZTROW6?4UKZ_4#[$7_@GU\&EZ:QX
MU'_<4LO_ )75\\_M>_LL_#_X"?LJ?M(?&WP=?>(;SQ9\)?@A\3_B+X:M=9O+
M>XTB?7O!W@[5]>TJ+4[>"TMYI]/EOK"".\BBGBEDMVD6.2-R''%K^W]\<&Q_
MH7@@9&?^0/?C'&?^@FW\NG?->>?&/]J'XC_'CX1?$_X*>-8/#L/A#XL^ _%G
MPY\3S:-875GJ\6@>,=%O=!U:72[J:\N8;;4$L;Z<V<\MO/%%-L=HG"XK.'C=
M^S<IUJ3K^$TI4HU*;J1_U(Q=Y04HN:7_  O1;O%-*S3UW5[D5>"OI$.G.,.*
M9*HXR4&\^I-<S346_P#8'L[-[GUA\!/V/OAM\3/@;\&/B1K^H^)[?7OB#\*/
MAWXWUJ"POK6*PAU;Q7X1T?7M1BL8I+.62*SCO+^9+2.2222.W$:O([@L?7E_
M8-^$2C']K>,#P ,ZC9<8_P"W"OACX=_M=_%+X:^ ? OPX\/6WA:3P_X!\(>&
MO!6AO?Z;=3W[Z1X6T>RT+39+Z>._ACFO&LK&!KJ6.&)))R[K&@;:.XC_ &[/
MC202UKX-ZX_Y!%Z.GTU$URUO'']FLZE1Q\)7&#G-P3X'Q7NQ<Y.*_P"1_?2-
ME\M^H1X*^D.HQ4^*).2C'F?]OTM6DDW_ +CU:;]&?6J_L)_"->FJ^,!SG_D)
M6?\ \@5*O[#/PF3IJOB_\=1L^^/^G#V%?*"?MR?&9NMMX.ZXXTB]]O74?>K*
M?MO_ !C.<VOA XY_Y!5X.O&/^0C^/_ZJXI>./[-%?%X22>G_ $0^+T^7]OHK
M_4OZ0UO^2GG;_L?TK?\ J"?5B_L/_"E<8U7Q;QC_ )B%IV]<6-3+^Q/\+%Q_
MQ-/%9Q_>U"U/Y_Z'S7RRG[;'Q?;'^C^$?X<_\2J\[_\ <0JVO[:7Q=.";7PG
M@^FEWG]=0KFEXZ_LRU\7A#)Z/7_47%NR_P##^'^IOTA^G$\__$@H]GWP/8^H
M%_8M^%R]-3\4_P#@=:__ "'5B+]C3X7QRQNVH>)Y45U9XGO[95D"L"48QV:.
M%8 JQ5U8!CM(."/F!/VS/BTV<V_A48Q_S"KON,_\_P#_ )ZU<A_;'^*^]&:V
M\+.JLK%#IMTN\9Y3<M^2NX C< 2,Y -90\>/V8T:U)OPC4'&K2:G4X#Q;A"2
MJ4W&<U_;T[P@TI27)-.,9+EE?E<2X-^D(XR3XEJ/W7[JX@HW=U)-*V!C=M72
M]Y6;6JW7Z>Z)H>E^'=+L]&T:R@L-.L(5@M;6W0)''&HP   ,DG)9CRS$L<DY
MK\XO'O\ RET_9R]_V%OVEA^!^,?[/X/]:^VOA)\6] ^*V@1ZCISI:ZK;*D>L
MZ-)(#<Z?<D<8Z>;:RX9K>X48=?E8)(KH/B;QX,_\%=/V<?\ LQ7]I8_E\9/@
M :_V%\-.(N#>*^$<ESW@#&97CN$,=D$9Y'5R=4(8&E@882C"CA:>'PZC'!SP
MD81P]7!SI4:N&J4IT:E*,H/F_E_B+ 9GEV8U\'G-+$T,SH9E".,ABN=UW7=:
MI*<YSJ.3J^U<G4552G&K&<:D)R4DU^F5%%%?4&(4444 %%%% !1110!P_P 3
MO^2;?$'_ +$GQ5_Z8K^O#_V&/^3+/V2?^S;?@G_ZKCPY7N'Q._Y)M\0?^Q)\
M5?\ IBOZ\/\ V&/^3+/V2?\ LVWX)_\ JN/#E;K_ '67_83#_P!,S.9_[U'_
M *\2_P#3L3ZHHHHK Z0HHHH **** "BBB@#\G+K_ )3@:-_VC&\0?^M,^'J_
M6.OR<NO^4X&C?]HQO$'_ *TSX>K]8Z[<9M@_^P##_P#I54XL'OBO^PNM^5,*
M***XCM"BBB@ HHHH *^=?VOO^33OVF_^S?\ XQ?^J]\0U]%5\Z_M??\ )IW[
M3?\ V;_\8O\ U7OB&M*/^\4/^OM/_P!.TS#$_P"[UO\ KU4_](F>;_\ !.+_
M )1]?L1?]FH_L_?^JN\+5]I5\6_\$XO^4?7[$7_9J/[/W_JKO"U?:57BO]ZQ
M/_816_\ 3TQ83_=L/_UYI?\ IN(4445@= 4444 %%%% !1110!\Q?ME_'C5?
MV9OV:/BK\;M#\.:7XJUGP/HEK<Z5HVO:C-H_AZ34-3U?3]%M+WQ)JUM;7EQI
MOAW2IM134]<O8+6:6WTRTN7C4, Z_!/C?_@K/X&^#/Q2TS]G;QQ\/I_C#\;&
M\'Z9K4.N? +6?!-Y\+_$OC/Q'K-C8V7@;0]:\8^+=)O/#VL3:3J^G:G<77BL
MZ=IKP)>NM^\<:Y_2O]H3QAH?@CX/>-=9\0^%]*\<:==:?#X='@O7K>VNM#\6
MWOBJ\MO#FG>'-9@O+2_LY-*UF^U."POUN[*ZMS:S2B6"5"4;\[;7QQ\"/"5[
M\--4T?\ 8@^"'AL>,/!&G^.?AUXWT_P'X/71O 7P.LKB:YMO$/Q U7PUX#O=
M7\ V\%UK.DQZ?INFV>HZ9;ZKXKC-W?60M=7GMP#SN^_X+>_!@>#?$/BS3OV=
MOCEXAT_1?$?P]^'5SH6FM\,9O$VH_%3QSJK:7J'@2S\+OXX&J7$'A6*WO9[W
MQI):IX+UZ:Q?2/#.LZKJTL%E)]1_ +]L7XD_M1^(O"/BOX3?LY:EX=_9XT_7
M_B%X5^)OCSXIZWX>T+QUIVH^&/#6GZAH4/@CP!H&I:_JMTEYK%\-"UBW\0QZ
M+<V-Q;W$20;(1/)0T%OV>_$>I_$>^^,_[/'[)VB^$Y]5\/?#?PQXGM])\(>+
MKCXM*5M/B;X)T5(=3\ :;!=::YU>#Q-H6GO?:A#;^(II=1L85F=;]V>&_P!M
M7P1X&@UWPEIWP)D\ 7G@S0(/B;XX\ :*WAKP_JG@_P"'FK^(K'PEI?BC4?#<
M$&E*VJZ]J5Q&VFV,41&HV.FZA-%?,+$*0#\P/"7_  6X^-Y^(WP_\":S\ OA
M?JL?QEM?!-O\-=3T?Q+J6@K>_$#QMXC^,UU!X!UZ>_CO-.TIK7P-\--*D/B&
MZNDA_P"$EU?4H;JT@M=.(;VGX:?\%6?B]\3M3U/P?<> _@7X4^(_P\^#?Q@^
M*_QNT'QGJ/B_2CIFM_#2^U'3[;X%> KJ>Q?3?B%XHBELTUS4/&&@:OJ?ABZ\
M.21ZGIEKND,<?O?[/'Q)^#'B#]HOQ?\ LLW?[ &D_"C2O!'Q$\6QZ#X^\2GX
M5_$7PQXF\5:?I.N^.3K'A74=%N_%$VD7JZ?K>NSW.@7EYI^L^#Y_$%QI[:=9
M1:A=1']%H?V8OV;+?2?#F@0?L^?!&'0_!VKZMX@\):-%\*O L>E^%]=U^-XM
M=UKP]IZZ$+71M5UJ)WBU;4-.BM[O4HV:.\EF0D4 ?E?K/_!3#XG^*O#&J:W\
M+-+^ &DQ>%/^"?)_;+\21^+_ !1JNIZCXA\3W?AWX@ZP/AOX)TG26M(+NP\.
M7?@A+?Q3JE_J O;,7]RC:?"]DLEQ^O7PC\50_$7X6?#3XBMI4&ES^._A_P"#
MO%\EBMN(S8MXET#3M=>R4./,$=M+>E$#$GY ^23FO--9_8W_ &3=>T"+PQ?_
M +-GP0CT2VL/$NF6%II7PR\(:#)I%CXRAN+?Q=;Z'?:%I.G:AH(\46]Y>6_B
M!]&NK&76+>\O(-0>XBNKA)/H;3=.L='TZPTG2[6&QTS2[*UT[3K*W01V]G8V
M,$=M:6L$8X2&WMXHX8D'"HBJ.!0!Y-%^SO\  Z'XMWGQXB^%O@V/XPZA'9I?
M?$)='MQXCNGT_0U\,V-W-=XVOJ5IX:5?#UOJAC_M&+0@-(2Z&G_Z/7LU%% '
MYB?\%E_^49W[5_\ V(VE?^IEX;K^?O\ X*2:->>)/^"BOQJ\/Z?!+<7VO>+_
M (::/:0PKOEDN-4^'O@.RB2- ,LY:4$ 9+;?:OZ!/^"R_P#RC._:O_[$;2O_
M %,O#=?SY?\ !3+4]0T7_@H1\>-8T>]NM,U72_$/@"_TW4;&:2VO;"]M?AIX
M)EMKNTN(BLMO<02*LD4T;*\;J&5@1FOY'^FG*A3\+^$*F(A*IAX<?49UJ4&E
M*I1AE\Y5(1<O=3G3A."OI>2;/U'P:4Y<69S&G)1G+A^,82=VHSEB6HR:6MHR
M<6TMTK'U'\8_V6?V?KGQ3\1? F@7_P -?AUX.^!/AO2-0\2?$_X>ZEXG^(WC
M;6O&$]QHG@&W\!>.-!U'6(M$\.ZUK_CG4KR]M[?3!YEM;68,S1Q)/%7&>(/^
M"=NA>'QYDWQ9UK3K'PG+XZMOBGJ^L>!!#9Z-/X$\"V'C?4KKP='#KC2^*M,,
MNHVGA87K?88Y-=<"$O"RY_,&+QGXNDA\26[^)M=>#QEJ5OK7BV)M4O"GB;5[
M74)-7MM3UT>;_P 3.^M]5D?48;J[\V:.^<W2N)COKUF]_:"^-^NV]Y9Z[\4?
M&6MVVH>$_P#A!;J/6=8N-5W^$C<V]V^B1/?FX>UM9KBUMGN7M6AN+G[/"D\T
MB1*H_@/'<<^&68SQN(S7P_<:]1MX58+%*A3A"%6H\-AYQH2PL53I4*>$ISJ0
MI.O6Y\7[2I)RIU%^]X?(^)L-&C3PO$%Z22]K[>CSS<I0@JE6#J*LW*I4E6J*
M,ZGLX<M%0BDI0?ZI>'OV#_@AX+NO"-EXMU_QIXRO?%7Q0\,KI.H2^'TT72K+
MP5H'P^3XF>/](\6VMOK4PT]_[*(TZ]OX;J6XL+R6&VM8I/WLZGB#]B;X;^,/
M%'A"P@UZ+X3V%U)X=\+O!H'AR^\1W/B+Q9XT\.:W\3A/,=0\1"#3]-\'^"XM
M+M]3ND=5P<BV:5PS?F#:?'?XT)97FFK\5/'RV6HZC=:OJ%N/%&K 7FI:AIT>
MD7UW<M]I\R66[TN*.PN-[,LMK''$ZD**UC\:/BS>6MA;7/Q#\5S+IE_J.JV,
M[:O=#4+>_P!6T6+P[J-P-41EU&3[5H$4>C/%+=/"FFK]DBC2$E3AC/$?PC^J
M/ KPTMA;X6;IQJ4859^QDO:49XV-1XQJIS5)JJJT'_"IU(3A3O*J7#W%GM?;
MOB7]Z_:I2<9RC'VBM"4:$H*C&RC&+CR22O.<)1E.R^M/CM^R#X?^!?@3PY>S
M?%BPU[XJZQXET?0[OX>II]K;Q&TURS-[;ZII6H)J4]U-9V$<UE'>SWMA9I)-
M>'R,Q1J\GT5X3_8A^'OA7Q3X8O?$GB?7_&-KX<\4^,M,\?\ AK4O##^'=$UN
M'X>^ 7\5>)[OPSJT>IR:A?\ A^QUZ]T3PV^H36=DMY=W-P('51$TWYE^(?B?
M\1?&]AX=TSQAXW\3^)=/\)1>1X9M-9U>\OX=$CV)%FP$\K&&01001>=DS>5#
M%'YFR-%'9:G\;/C!XD9/[>^)_CK5]FFWNBH+_P 3:M.J:3J<=G#J>FHK7.Q+
M/4HK"R2_@4!+Q;2#[1YAB7'Q4>-O"'"9SF68P\.<3+!1IY/')\!4QWMHT:F#
MBYXZOC7B*\X5:V*Q'*I<M.="K1AR.A2YI7]AY+Q?6P6&P_\ K'3C6<\;+&UH
MT'!SA6?+0I4/94H2C"E"]KRC4A.7,JL^6)]UZU^PEI&FM=77_"S;W3K+PW<>
M-1\1+F]\'2)9Z/%X2\*Z7XJOKSP;#_:@O/$^B6UQK=AX7-[,EA(^J_ZJ*0,%
M;5\0_L0>#?!WA?QGXJU_XRG1[/3= ?5/!]IJ_AVWL;[5=0MO!VA^*+G1]<MC
MJTDEA?R7.OVFDVUKI8U659$D><QN%B?XANOCA\7]8@N+?5_B-XKU:*Z\-2>$
M)EU359]0)\-2SV5U/I$;W9F>"VN;C3[*6Y:!HYKDVL*SR2(@6M!_C!\5-0T;
M6?#U]\0O&%[HGB*Z6\U[3+S7M0NK75[H01VPEODFE<SLT%O;Q.KL4D2W@$BL
M(8]OFYEQOX'2CF4L/X88V5:O@\7]3E7S2K&G0S">&KT<-.I2H8N">'A.K"M.
M--I^WHQJI.$G071ALDXX7U=3XHH1A"O2]JJ>%C*53#JK"I449U,._P!YRPE3
MBY1M[.<H7NE5?W]^R[^S1X-\3_"O5==^(/A_2M7\3>--$UCQ'X)MKS4=8L[K
M3O!6BV^HZ+=^)+>[LIK72;&XL_%4FG7UU%?OJ-_+H&GZB]GI4DCQ+)YI\"/@
M3HWQ&^&OB+4=6NK/3+K6?&B:!H7C*>UO[N/P]H?@WP[JGC+QOJUO9Q75I'="
M73K&UL1'<PLX>[BC1K>20&OFC0/C!\5="\/VGA31/B+XRTCPY92R36FC:;X@
MU&RL;9IG:2988;>>,1P2RR232VRXMGEDDE:+S&9C)X?\>^,] TV?1M&\2ZOI
M^D7-IJ]G-ID%V_V P>(+5+/6_+M7\R&";4[6)+:[NH$CN7B55\T  5\W5\0O
M"F%+@S#5. <35P_#_#V;9=G7-++XULYS',XX>4<36KTX1K58X:JL6J-:I4^L
M4:5:BJ/LY49.?H1X?XK<\ZJPS^C&MC\QPF)P32Q3IX'"X5U%[*-.4I0@ZD'1
M]I""]E4G"HZG,JD5'ZBE_9PT.W^(]KX6@\;:I<>%+?X/VOQBU[7!X;'_  D%
MIHTUA<Z@^E6?AR*^E-QJTT2VK6L$EY&0EXAFV^60?1-#_9*T[Q)X:T_6?#GB
M[Q =1\06.C>(O#MAK'A>"TM?^$;UKQ-#X8M+75KZWU2YB@\5/-'>:@=)M#=0
MI9VI,MRLDC;/CW1?B'X[TKQ!#XLT[Q=XBM/$L-BFF1ZY%JMV=373HK86<5A]
MJ>1Y#9Q6J1P16S9ACB1%1!M!KK])^+OQ/T^WTBSM?'?B=+/0M3FUG2+.75)[
MBTL=5N&FDDOX;:Y\Z$W!ENKB96:-ECGGEGC5)F+CYS!\8^"%*KCY9OX<YE6H
M8K%9A4HT,-C_ '\'0KRRZG@X4:\\9&2^KT*6/GR2A42Q-:G/VE2+E"GWU\GX
MXG'#+!\286%2C1PT:LJN'?)7J4XXN==SIK#23]K4EA8\RG!NC"<5&$HQG4^K
M=._93\.ZE-?P>'/B?-KVHZ1=:2TVCW'A*ZTA[W3;SQDOA-KV&]>_N8HH+Z6"
M]GT<LCSWL-K+-Y$4($A]%\1_LP>!]?UV[\4^%O$&N:)X$N+R^MI?#\?AEY?$
MUA-;>*(/!&FG1]-N=2\^]TC5-52\O?[4OY;5TMH9)1#M>-5^+_\ A;WQ'NKB
M6[_X2S4K.XN+7P_9S3:68=+E,'A=YI="5)+"*WDB:QFN[F97A=&EEGD><REB
M*V(OB[\4&UF;Q$?'_BPZW<:>-*FU)=:O%NGTX%F%EN5PH@20M*B*@"3,TRXE
M8O6J\1OH]T,'5P5?PHQE>%;'T,34JTL5R3Y<,\4L-4HU<1F-7%4HJ%6G3QF!
M5=87':593H3HP<\Y<.^(=2M&O2XLH4Y4\+4I1C.G=.57V'M%.%'!JA-N=.<Z
M&)=/VN&;Y(PJPFU'W3P#^S)<>-_&'Q-\(VGB=%;X>>)=&T%=5BLHY;348+_4
MK^WOKZ4&Y M?L-A82SK'YDBSW12U$BEU8]'=?LXZ1X)\916WBW7+N[\,>%=.
MU7QCX_G-FMA]F\,VVJ3VOA/2XF6Y9QKGCA8(A!8,\4MM!<221R.82:^5=$\8
M>*O#_P#:"Z%XDUS1UU>2*35?[,U2[LVU&6&0SQ27S02HURZ3,TJM-O8.S-G<
M23J7OC;Q=K46J0ZOXEUO4X]<DL)]8&H:C<WC:E+I2/#IKWKSN[S_ &*)VCME
MD8I$N%"X5-GQ.'XX\#\)D>':\+LQJ\4X;-L=F*QE?.E7RF>$6.S#&95EE7!5
M)<U6C1A+*\+C)S3EB,/AL3!).NI'IU\CXXKXVHEQ5AH9;4P=##3I0P3IXI5G
MA\+0Q>*IU8P<:=6<XXVM0C"7+2JU:#UC2<7]S_\ "EO 6J>!/">OV'ANQM?%
M/CT6-E9:-%>:I-!X6;XCZS?77AK7-8'GH5L_#OAO3S;Z;"KR-?:A,PO(RHCD
M; G_ &5O#DDFIS:#\3(M4TS0(-#O/$=VVFVZ'0+*\_MJ;6+C4&AOI;96LK'1
M_M%K LYDFDN$@G6$E&?Y)M/'/C.W>)H/%.OQ,G]E[-FJWHVC1 3HZJHFVA=,
M)(L4 VVX+>4%W$'N;?XQ>-7T/QSI%_JVH:K=>/XM)LM9U>_U*[FNETW29Y;D
M6,,&X6Y2Z:7RI9&7,=L9H(U"7$F?J*OBO]'W/84X\0^$KP];#99&$*^#K4\'
M"MC<%E.(J.?+E,L(I5L[SV.%^LO$4JM'"X&=2GAW04%S^(N%./\  2D\#Q9&
MK"KBFW3JQJ5G"C6Q=**CS8V-9J&!P$JSI>SJ0J5L1&$JOM>9\OT)JOP$^'2Z
M?IDMOXD\1:.FF^$_"FI:[?W6B1W3ZGKOCK4E3PSIMI;+?E(;J2V>5;J-";:T
M6&&1[F0RR^4V7]F6QM)-5>Y\5ZF;+1[OQ*TRVN@>?JE_I/ALZ9ILMUI5DUU&
MEQ<W7B'4ETZWC>5+<0QO<O-@;:^8KKQSXQU*UM+*_P#$^N7=E:)I\5M:SZE<
M/!"FDLYTP)$6V9L"[FT<JSPEB48'!'0+\4?B,^H)J[^-_%#:E':S6,=\VLWI
MN([.Y,;3V\,GFYBBD>*.1UC S)&D@/F*&'S>(\2_H\8O%2KXSP=Q=-0E@?8?
M4<<L/&7L\/&EB'B,.L?[&<:4\/AYTJ<.26,E4QD\75BZRY>E<-^(5&DJ=+C"
MC.3]NZBKT)U&N:HYTO9U7A'4BYQJ55-R4E04,/&A":IR4OK;Q'^SOX/GU:\2
MSU34O#NG:9IUYIUK]CTD:BEQ>>$O#UOJWB'7?$=S)?\ E:;]KO+V'3HK:!IF
M^UJPC78N:^*XCD9]0I_,5T*>/?&SV.H:8WBSQ$VG:M<W%SJEH=5NS#J$]XBQ
MW<EZI?\ T@W2@"=9"4EVJ6!*J1S\??\ #^M?DOC#QEX=<88O*L5P%P1+@^</
M[0JYSS5:4H8RI7K4HX*C0HX>I+#TJ.#PU"*BX4J,I3K5(RC4Y?:U/H^%,GXB
MRBCBZ>?9VLWC/ZNL$E&HG0A3IS]O*<ZL(U9SKU:DI/FG47+"+3A?V<-&+K^*
M_P S6BGW1^/\S6=%U_%?YFM%/NC\?YFOPFKU_P +_4^OZ/\ Q2_])9>C[_A_
M6M&+K^*_S-9T??\ #^M:,77\5_F:\ZM^B_,/MK_M[\Y'=>!_&NO^ ?$%IXB\
M.WCVUY:D"6(EC;7ML6'FVEW$"!-!*!@J?F1@LD96158>JZ9X^M/B5_P5#_9@
M\4VMG<V#7/["O[3$%U:W$<BB*\@^,?[/ZSBWE956[M@QW17$6Y''RMLD1T73
M^ 7P%O\ XEZA%KVN1367@NRF DE(:*76YHF!:SLV(5OLRLI6ZND..6BB8R%F
M3H?%6G6.D?\ !67]F?3-.M8;*PL?V#_VD[>UM8$6.&"&+XP_L_A$1% 4*HXX
M[@DG-?[T_LJ_#WQOX=R#B+BGB3,L7E/A)Q#EN*J<-<)YM1KU,5F>9VI\W$>5
M4\1.$\GRV5*,J,Y1I*&;R<:D:*A1CB9_Q;](_.^$<?C\NR_+\/3Q/$F!Q="&
M8YGAI05*A0YI..7XEP36+Q$9-35Y.6#5X.HW4=&'Z@4445_K<?SJ%%%% !11
M10 4444 </\ $[_DFWQ!_P"Q)\5?^F*_KP_]AC_DRS]DG_LVWX)_^JX\.5[A
M\3O^2;?$'_L2?%7_ *8K^O#_ -AC_DRS]DG_ +-M^"?_ *KCPY6Z_P!UE_V$
MP_\ 3,SF?^]1_P"O$O\ T[$^J****P.D**** "BBB@ HHHH _)RZ_P"4X&C?
M]HQO$'_K3/AZOUCK\G+K_E.!HW_:,;Q!_P"M,^'J_6.NW&;8/_L P_\ Z55.
M+![XK_L+K?E3"BBBN([0HHHH **** "OG7]K[_DT[]IO_LW_ .,7_JO?$-?1
M5?.O[7W_ ":=^TW_ -F__&+_ -5[XAK2C_O%#_K[3_\ 3M,PQ/\ N];_ *]5
M/_2)GF__  3B_P"4?7[$7_9J/[/W_JKO"U?:5?%O_!.+_E'U^Q%_V:C^S]_Z
MJ[PM7VE5XK_>L3_V$5O_ $],6$_W;#_]>:7_ *;B%%%%8'0%%%% !1110 44
M44 <AX^\#Z#\2/"&N^"?$L5Q)HWB"R:SNGLYA;7]JP=)K>^TZ[V2&TU"QN8H
M;NRNE1V@N88I0K;<'Q-OV._V>#:^(K.+P/J=E;^*M6M]8UE=+^(?Q,TAVEM;
MB[NHM+TV;2_&-I-H/A9KF^NI[CP7H,FF>$+N617NM#F,4/E^V^/?'O@WX7>#
M/$OQ#^(?B72?!_@CP=H][K_BCQ/KETEEI.B:/IT+3WE_>W,F0D4,:DA0'DD<
MK%$DDKHC>;?#7]IWX!?%Y9S\//BEX8\0/:Z1X8UZY@,]SI%W;Z1XUU;Q!H7A
M&]GL]=M=,NHD\2:OX5\0Z?HZ/"LM_<Z5<I;QN/+,@!Z?H/@KPGX7@O;7P[H&
MFZ+:ZA)9R7-KI\ MK8MI^EV>B6 @MXR(;2.STG3[*PM8K1((X+:VB2-%VYKP
MG_AC3]FUKZ/5+CX<M?ZLOB ^)+G5]5\8^/M7U?5KP3-=0Z;XAU35/%-Y?^)?
M"5E=NUYIO@3Q!<:GX)TN\Q=Z=X?M;E5E'3:/^U!^SSX@3PI)HWQB\!ZA%XX\
M6?$CP+X6EM]=M3%JOC#X01>*Y_B?X=25RL=KJ?@B#P-XNF\06]\UJ;*'0-1E
M8E(@S=WK_P 4_AGX5MK.\\3?$'P5H%IJ+:(EA<:OXGT73X;P^);N.P\/-:R7
M-[&D\>MWLL=II4L9:*_N'6*V>1SB@#S_ ,+_ +-WPZ\,?$:?XL;_ !'K_CZ>
MZO[Q]?\ $6L"\E$]]I3: KK:VEI862M8^'WDT.R?[.91I\C"Y>ZN=MROOM<Y
M-XQ\(VZ2R3^*O#<$<&H3Z3/)-KFF1)#JMM$)[G3)7>Z58]0MX")I[)R+F*(B
M22-4Y+1XR\(LMVT?BCP]*+'1%\2W@AUG3IFMO#K))*NNSI%<.\>CO'%*Z:DR
MBS=8W*3-M; !TM%?$Z_\%&?V)C8:CJ<O[0W@>VLM&\$:7\1=;N9SJP@T/P=K
MES8VFBZOK-S'IDMKIC:Q/J>FIIFFWD\6JW_V^T:VL95GC)CNO^"DG["%CHFN
M^([_ /:G^$5AHWA?X;O\7O$=[?\ B-;(:%\-8O%-OX(N/%VK6]U!%=6&F6GB
MZZMO#UZ+F".ZLM4FCM;JWA=QD ^W**\\^&OQ6^'_ ,7]%U7Q#\.?$UAXHTC0
M_%GBGP-J]W8^:HT_Q7X+UFZT#Q+HUS'/'%+'<Z;JEG-"Y*>7-'Y=S;O+;S12
MOZ'0!^8G_!9?_E&=^U?_ -B-I7_J9>&ZZ7XS?\$P/V7/CW\3?%/Q?\?V/C>3
MQAXTETNYUI]*\6/IVGM+I>B:=H5H;:R%G*L %AI5JKCS'WRB23C<0.:_X++_
M /*,[]J__L1M*_\ 4R\-U^3_ .W[^WA^UE\(OVP?C/\ #CX=?&#5_#7@KPQJ
M/A.WT+0K?2/#ES!817_@'PKJUVB3WVCW-W()M0O[NY;SIY"&G95*H%4?C7CW
MQ3P#PEP1D^8>(?#,N*<HK<15,-A<#'#8;%.CCG@74AB.3$UJ$%:E"I3YE)R]
M^R5M3Z?@;*L^S;/\?0X>S195BX991J5:_MJM'GH*O*+I\U*G.3O-QERM6TWT
ML?IZO_!&K]C!/NZ?\1AG_J=W_P#E?ZC]?KBRO_!'3]C5,;=.^(G'3_BMI/?_
M *<,<D?K[$5^!<'_  4O_;?;[WQYULXZ_P#$B\)#U[?V#[5M6_\ P4F_;8?;
MN^.NMG)(/_$C\)XX_P"X%P?\37\;5O''Z*]/^)X+UG?_ *DF5:_?F"/V&' _
MBC+6/&J7G_:&-_\ F=L_>-/^"0'['<?W=/\ B#^/C60COV^P8[#\_:K*?\$B
M_P!D).%T_P ?<=,^-)/IQ_Q+QZ?KS7X76W_!1S]M%RN[XY:RPR <Z'X4]LYQ
MH8Z9_P :WX/^"B'[9+XW?&W63G'_ #!/"WMZ:(/7Z5Y5?Q\^B7#^)X(UI?\
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M:+]L/]H\@9^)VHG.23_9>@_G_P @OT%>)5^E!]"!?%]';%2Z7_U=R%W?:_\
M:NK:Z7^1VP\,O&MJZ\0XKK;^U,Q3UZ_[GMYV];'Z8K_P3N_9W3[MIXL'3_F9
M7[=/^7>K _X)\_L^@ "U\5\ #_D9'Z#I_P N]?FG%^U]^T8V<_$O43]=,T+M
MCTTP>M:$?[6_[0YQGXDZB><<Z;H9]/\ J&?_ %_>N"I]*3Z"R^/Z..(;Z_\
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M[%=?M%6=IH4.@KXLA;2-5\,6_P <-83X60WUZUWX.USX>:#J%C!)=V=V;?\
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MN2F\A@4?K90!_/K-_P $4_B-XF^%>M_"G7_VN=3\'>"O'?@'P[8_$#P'X$\
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MU#S?_E6*_4^I****YSJ"BBB@ HHHH **** /R?NDQ_P6\T9_7_@F1X@7\?\
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M[\>?]B=XF_71;T5XQ^Q2-O['?[*R_P!W]G?X-#\OA[X?%=*_W*;_ .HNFO\
MRA49Q.5\?!=L+/\ ]/TT?3E%%%<QVA1110 4444 %%%% 'Y77*Y_X+4:,_\
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MMHVH>&[![--86_\ #-ZNOWD<0!^?_A7_ ()$_L1_$SQQXVF\)?M&?'._\3>
M]7^&\NILWA[P)IU]\,X/A ^F1^'M%\)>(M9^#EG=^&FM-.LY=*M+O0=3.JZ1
MX6U2;2_#USI^AFUBC^G;O]F+]ESX3>"?V=M"\+_M-_$+P!KOPW^-7Q@^/7[.
M?B_POIW@WQ+XPMK'X]Z_XMOOB;X(LO#X^&WB'3/%_@C5XO''B?1#J6O>'-3\
M3Z1IE[;R)XC@GTZRNX?OG3/V=[6WT77-*U3Q]XVO[O6=<T?Q!/KVF:Q?^%]9
MU+4M*\$:1X.ED\47'A^\LH_$EOJTFEOK>J:==10:9=7UTR-9A(U8_,.I_P#!
M/1M.U;X,^)OAY\5)-$\1_"33I;$R>+=*\9^*](UZ2ZNIIKJY@M-,^)_A35/#
M<?ESR)!IFCZTFD;PAO;&^@06U 'PMX1_X)P?\$^H[_X]ZGKO[4WQ+\;7WC?6
M[[Q7\2-0\=ZIX*L+W3+F-H])CUJTU*7X<:-<W<GAT*=(E\5^?J5]9-&MGJ^K
M&2P@2W[W1?\ @CA^R+\6[+1+W2?C7\3O&GA_X;Z!\:_@CHZMI_PHO8-&\&?$
MR?Q9JVJ^%K34[GX8B]FUCPKJGQ$U/6O#7Q(@N9_&=W!<6-IJ/B?6-'4VLGU9
MJ/[ GB;3+#QU=_#GXY2Z#XO^)6AZQX<\57_C/PSXD^('A.TTKQ3XX/BOQA;^
M"?!U[\2M+B\")X@TEI?"\\7AS4[2%;>:75YH[G5O+N(_K+]GWX3:K\(/#_C/
M1=6O-$NSX@^(_B/Q7ID?A^WO+/3;#1+^TTC3](TY+2]>:>":VL])03(UU?,"
MRK)J%](KW,@!\*_M"_\ !)7X2?'V;X>:7+X\\3>"/!W@GX _#[X 7FD:#H/A
M#4K_ %C0/@[XWT_X@?"N_ \1Z-J_A.(Z/KZ:Q)X@TN^\'ZGIOB&WU*.W\BPC
MMR)><L_^"/W@+P/\*_&/P6^#OQY^*_@GX8?$K0O@SH/Q(\ ZW9>"O%OAGQ5)
M\)=1^'EF_B>&23PYI?B7POXCU_X?^ +?P4UMX6\0Z1X/L%OO[73PK/=VD"#]
MAZ* (+6VAL[:WM+==D%K!%;0)DL4A@C6*-=S$LVU$49)).,DDU/110!^</\
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MTK\&(?B=\2\C=\1?'AZ<'Q?K_?@Y/V^M.#XF?$AC_P E"\==?^ANU['4<_\
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M'AO7?">N:1XI\)7[:9K^CZIH/B.PT[5;&[T^\4Q2+<6B!N&C+*<U[/\ (!T
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M[!NK>(?'?A[X1^.?VFO!UY\.->\*M>V6C^*+GP-HGP[7P+\-;SX30^'?"N?
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M[WXE_!J3!YR2!&23QP.,5WY;7PW_  H4W@J:J3P.82IU_;U^:E#V4&J4:?\
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M3+KQ?<^%F^)VK^"-%@^'=K:VUU<6R^*KG5X_$4EVGANY6!;F"[6Q>9K>>%S
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M7A*W\6/XEL[GPQK$\-SJ>A:KX3\6Z[X.UC3[R>W1(97CU/0+J2-XT4-!)$2
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M?B):S2V]UXU\?VUQ"P26WN?%?BB">%L9V2PS:BDD;;2"5=%."#C!%3C/IQ<
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MWB\?KVYK^8Z/Q7XJY_XJGQ-V_P"9@UCW_P"GVK">*?%!SGQ1XG[?\S%K'O\
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MC355^"^=>S<Y4U4_UHPGL_:17,Z:G_9/*Y*+NXJ3DD[N*3N=7_$LV-O;_6_
MWY5*W]F8B_*WH^7ZU>S>E[6OI?H?T4>=%_STC_[^+ZCW^I_"D\Z/_GI'_P!_
M$]O?W/Y>]?SO+XE\1X!_X2/Q"<C/_(=U0]?^WK'^/L*M1>(?$\A2.+Q!XDDE
M<JJ(FM:K(\C-@!41;K<6)X"J"2> /7)?M:,D<HPCX+YS.<VHQC'BG".4IO11
MC&.5.4FVTDDFVVDHMZ _HS8Y7;XNP225VWE==))J^K>+25EJVVDNY_0QYT7_
M #TC_P"^U_QI!-%WDC'_ &T3V]_K^7O7\]__  D?B9&V2>(?$2,C;75]:U5&
M5E.&5LW0*LI!# X(((//%64\1^(B3_Q46O\ 3(_XG>I^H/\ S]<_A6<_VMF2
M4[J?@KG4>63B^;BK"*TDW>+OE*2DK:IM-:W2!?1FQKVXNP6EO^977;=]FK8M
MW7GJO,_H(\Z+_GK'_P!]K_C2>=%_STC_ ._B>WO]?R]Z_G^7Q)XCR/\ BHM?
MY(_YC>I^O?\ TKFK"^(_$>1_Q46OYR/^8WJ?KZ?:OZUB_P!KED2=O^(+YPWV
M_P!;,%?_ -50W]&7'+_FKL'NE_R*L1U_[FC]%IK-?^'C6G:GD%1^QSJUKYF1
MMPWQATML[^F"P"DGC=@9!XK[C\Z+G]Y&?^!J.YXY(Z<?S[U^!,>IZS+>?V@F
MHZM)J$5J;=M02^O'OX['S%E>V-Z)#=)9>=ME: S"W\W;(4WX-:*:[XE"B5M<
M\0^4Q9$D_M?5!&SIM+(KFX*,RAE+*"2 RDX##/1B?VO&38B%"I'P.SY0H82G
M2<_]:L*X2A0G.,JBFLFY5!3K*#?-:,K1<N:2B_.P7T7,5@Y8J/\ KE@92Q6-
MK8JW]EUTXSKJG[G^^7;2I-IVNU=VLFS]Y?-ASGS8\_\ 71?Y;L4X2QDX$B$^
M@=2?R!K\'T\1>(.<:_KO;_F,:A[_ /3P*V] \>>,/#VKV&LZ9XBU=+VPG6:(
M7&HWES;2!2=T-Q;SS-%+#*N5D1P<AB00P!&&!_:[\*U<=@Z68>#V>X/ 5<50
MIXS&4>)<#BZN%PLZL(U\13PO]G4OK$Z%*52JJ*JTW5=-P4XN29V5_HSYG"E5
ME1XJP-:O&$W2HRR[$4HU*BA*4*<JOUF?LXSDHP<W"2AS<UFDT_W(HKQ'X+_&
M?1?BKHBE6CL/$EA&B:QH[."Z2'Y1=6I8YFLYB-T;@$H3Y<FUE^;VXY[#/MTK
M_5S@+CWA7Q,X4R?C3@O-\)G?#^=X2EBL'C,+4A/EYX0E4PV)IQG*IAL9AJDI
MT,5A:\:=:C5ISC.'PRE_.>;Y1F.19CBLJS7"U<'CL'5E2KT:J:::;Y9PEI&I
M2J12G2JP<H5(24HMIM(HHHK[$\T*\E^/,7G_  .^,$)Y\[X7>/(L>OF>%]37
M^OZUZU7G'QAB$_PF^)UOC/G?#_QC%CUW^'[],?\ CPK2@[8C#OM6I/[JM)G)
MC8\V$Q<?YL+7CY:T:J?X,\^_9'M_LG[+?[.EKC'V?X(?"Z'&,8\OP9HZ=.<<
M '';..U?0Q4,&! (92I!&1@@@@^QSR*\5_9LM_LG[/GP0M<8^S_";X?0X]/*
M\+:9'C\EKVRM,6[XS%R_FQ->7WUZC,\MCRY?@8-64<%AH6[)8>FK'QG\//"G
M[<6F_%^6^^(7Q-_9\U7X$+J?B9K3PEX3^'?BK2/'D&ASO>?\(E9G7KOQ%=:.
M;S34>Q76)UTQ8;UHK@VT4 D0*OB[PQ^W5<_&;^T_!/Q3_9]TSX%?VYH\I\*Z
M]\/O%M_\03X?CAMAK=I_PD-KXCMM)_M*ZG6Z>PN?[-\BWCDA66.0HQ/V71SV
M_EG^HK5X^HZCJ?5\#=TO86^I4N2W_/SDNU[?O6^.^MC#^R:2I*C]<S-)8GZR
MI+'UO:7O?V//RW^K+;V%E!*RN?(7Q_\ #?[;.L>*-,G_ &;/B=\!_!GA*/1_
M*U;3_BEX"\4^*=9N-<-RS?:K2]T+Q!I-O!I_V79']GD@DF,H9_,VX%;_ ,;]
M!_:TU7POX#M_V?\ Q_\ !OPCXOLRW_"Q=0^(_@SQ%XDT76!_9<,:_P#",66C
M:WIESI9&L"XN&^VSW6;)XH.)49V^G<>Y'Y?X4O?_ #S4QQLXJ@EA\$_J_-R\
MV#I2=7F33^L:_P"T6O>//;E=FMBYY93F\9?%YC'ZYR<W)CJT?8<C37U1*/\
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M2"5-.6XVP25[=H.D_LY_ 71'TKPC<_#*PT*37-,\9KXBL/B)I&O^._B1X/\
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M?$WQ':6UU>:FMQ;Z;JVL_P#"+Z#>3O?60.IB\M$NK>\5E')Z[\/_ -DA=/\
M''BW^R=$\-KX%\66&GW7A"7Q=:W5SXDN)_"-M96]MH=EIVM:K<+X?D\6ZQ::
MA?36M]?""UTJ^$UQE9XT_*&-%&[]WCI_RS/J3_=]26SZ\]:T(XTSGR^5& ?+
M.0#G(!VDC.3GUR<U>,\<\-BL/['$^#/#&)JJIBZWMZ^5XFI)U\1"52%6-LKC
M.DJ6/J5<;4H473P^(E4E2K4^6S4T.!ZU*?/2XRS2G"U&#C#$4HKDI2C&47_M
MC4N;#0A0A4J*=6DH\\)-MQ/U[UKX-_LN6NO6OAKP_P"'_#5]K?ASPGKVN:+)
MK7Q%TW3O"GQ$(N-(TW3&\1ZE#XDO71H#>7VOS+&^BRW%I;?9;>R,2R!?)/B/
MHWAC7_VM_ $MQKG@6/X7+=^&[+2AH_B+3+C3M(\'?#VUBM;RTU&87 @M#=W]
MCJ#Z;%=W,MS?VTT#AG\Q=WYWQHH# 1\''_+,],$8Z=,'&.F..E:$<:X91& #
MMR/+P#C(&?EP=O8MP!7A<0^,F#S?!T,)@_"3*,DA0XCR?/ZD,JPN)PM'&PR2
MK2J8/+\;2HY-&>(H<L:E*HW7BIJ4:LJ3KJ=2IWY?P;6PE:=:MQ=C<;*>68W+
MX2Q4Z56I0ECZ<H8C%8><\?*-.IS.%2$?8RY7'D4U2<81_4^TO/A7^T'<^)/&
M?B?Q))K&@>'_ (@6\VGV/Q"U[PWX7U+P_P""QI^KZ]KFEZ#INGG3A>Z=K=];
M:-HFEH$N]1B0!9KA2KN>>^,7B7P=H/P+;PGX;U?P\]S=Z=\./!EE;:/J%AJ%
MU8V$TE_X]\6?:1:SS3/!;75WI^D27;C;+-:/;/(90R#\X50-G<A;IU0GU]16
MC$@7)5,9]$(/4G)P/4YZ]>:X<Q\=,QQ>4YMAY>'>7T\]S_+L7@,XXAIX;,%B
M<4L3B*L^:-.672E3ITL-5^K4J+Q$U34(2A**C&G'3#<"X:CC,)4_UBQ,L!E^
M)H8C Y;*>']C1]C2IQY>=8F*DYU8.K4FJ$'+FE&2=W-_J_IGP.^!]_<>&O#E
MAX;\(ZJUGJ#:K%J6F^/(K[5_$O@_0_ PUC6=3\7M'J)L]!BUKQ1>VVEZ<)%M
MA9PPG>\384Z.G_![X!1V7_"7:IX4\&0Z?'=^']&\96W_  G$_P#PC'A6?3_#
MMWJOC*Z\*WZ7XN?%.H6LMQI^F&VL9+Z-M2PX4"-\?EQHFNZSH"ZJNC7USIHU
MS2KG0M7-J#&;[1[QX9+JPF8+N,$[0QF101N"[6.TXK2E\0ZW>:%I/ABYO[F;
MP_H5Y?7^D:4X_P!$L;S565]1N8DV_P"MNF13(S$],# )KV*'CEP30P<75\"\
MIJX^GA)\E.64T:F#^N8:GA<-ERE.60JO*C[#Z[4QDY*=2I[2G14)U;XZ''/@
M7/)UI*/'6,C0G6CS26*J0K>PK3JUL4XI9E*G&HI^PAAXQY8Q49U)2A%K"R_0
M7PQX#_9[NM:C\-6FB>%-4U3PIX2\):O?:AKGCD6.D>++SQ/J$;:_)<3QWL=J
MK>"= $MV;*SE-Q=WTZ1S0N;=4JWIOPV_9EN+OPS=KJND2Z)XOUK5O#&E6K^(
M4CU"S$'BK7KQM;UDR3BYTZ!_#NG:/H>DW%WY(,NL?:FR\:R'\Y8U7;@)W)QY
M9XSC)P5P,GJ>_?K5U%4,Q*8R,$[""<$<$XYQU''%?'+QMRJ%.C"MX$\(5Y8?
M$3K0E+*,532I^WP:H4;4LHA*I[/ T:^&JNO.JJ]6M3Q<HQJTIQK>L^",9*4Y
M0X\SJFJE.,&EBZ4O>=.O[2?OXYJ#EB*E.M",(P5.G3E03=.HG2_0'X@6_P -
MO ?@;QM>^&;7P9X?\8:UX#T+PO=:/X5\1Q>)+9KOQ-XGO;C4+:"22YNW-QIW
MAS0[.+4KN#:OVK4)1N -L#U^D_!3X(:;H'@G0?']OH6@ZQK.D> ;D:Y)XI:+
MQ%K'B'4VN-;U_1+S2DNUC\/Z9'I#6NG#4+Z"S9IKR"196,43'\UX@J,&50I4
MAAA,88%2#@+CJ <XP<<UOZ[KVL>*-6N]=U^_GU75[X0_:[ZZ"O/,+:"*U@#G
M: %BMX(84   2-1CBG3\;\D>.Q^:X_P9RK'N. P.4Y-D%?+:CR3"8:685LPS
MO'5E#)*<UF./DL)2C/"T,*H^Q]HZBCST*V4^!L?&CA\+A^,\913Q.(Q>.Q\,
M1%8ZO66%AAL!0IMYA./U;#1=:;5:K6;4U'D<E&K3_1.WT+X7Z0?$R:/X2^%L
M?B.?X>:%9:QI">-H[[1+>Y\4^*9['4Q87]SJ20O=Z%X>M%N;Z2WG%TU].D4?
M[B50_%?&#3/ /Q'\9_#/3/"&GZ9#K?B+QQ>^$)KC2M96^-WX0\,S:3X?TZ\U
M*VCFGBL9KP6U]<V,D2Q12:>@N ',SRGX20+NQL7'.1Y8 YZY&W')QGZ#/3C<
MT'6M3\.:I:ZWH=Y-INJV$OFV=];*%FMY#&\+/&2N ?*=UR0>&..U<N;>.N$S
MK+/]7<5X3Y;E^08O,<NKYC#+LJC]<AA,'G&$S&K]1DN'L*J6,K4*%?#3JRJJ
MG*6*J25.%-SI3>$X#K8#%?VG2XMQ6(S&CAL33P[Q6)?L95JV"KX6G[=?VG7;
MH4ZE2E4Y(Q<^6A"+G*:C57Z2Q?"[]GM_%+6.H:+X:TS5]!B\2W\/A+3O&$6H
MV6NZ-#JUKIVAW6M7\^LV5JFKR68NM4.E0:G#Y$6%N4/EF(\5:^ OV>F>9;O3
MK72[3Q'I&O:_!?:AXP/V_P -6=SXGL]$\-Z986D=[-I]S?")=0O;J8_:##9B
M,AY(OWI^!0P<N[Y9G)=F<,69F)+NQ(R2Q)W$YSD@YJPHSC<N< !,@G:!G &1
M\H&>@X&?K2S#QYR*O).A]'_A"G"GB\56BZF33G4KT:RA0@L5*&1TTJL<%35"
M3PT:-'G_ ']*G2KJ=:H8?@3'TE'VG'V<3O3I0LL7[L)4W*K+V:EF,KQE6DYI
MU93J<MZ<YU*7+3A^HC6W@'PSI;>%M"'@OPU-&WB>>"UTCQ99:Q+?3:[?V'@?
MPOJ%_>O>7!EU=M'EO=9O;2+]U;(Z,RI@FL7PG\*O@7KEY'%I7AW3YX-(UGQ=
MIJ//XDN-275?[.N],TG1VUJ.?5;+9>^(+M-8?P_IJ75HMR422%9XXCG\W(U"
MMO"X/4,JX(88P00,Y'J,'WKN_!WQ!\8^ VU&7PEKUYHCZLD$=^;98W^T_93(
M]K*PFBD GM7EE>WG7$T+.S1NI)KV<'](KAS'YSEBXI\%,J?#N IRH4Z.%R6.
M88G!8>G2C+"4L#A\5DN$P=-K$TJ7MY1A3]K32]I[1QG&KYM;P\S+#X3$_P!E
M\:8K^T*[52<ZV+EA:->I-S56>(JT,?B,1)>SJ3]FG.?)+2+CS1E3^D/"'@?X
M=>-_&OQ8@N-,TSP7I^CZAH&G>'?#^NZY#H\NEV;>(HK77K^:6^NP)+^UTJTN
M'D@CFF6.XNU5!@H3ZW-\+O@E::38R:_I6C:!H?BI+F[TKQ-_PDI7Q!:_VSXN
MBM/"]I9:,]T0+*+PZ&O]1U*Y@-ND3 K,^UZ_/*>XFO)IKJ[DENKFZFEN+F>X
M+RS3SSNTDLTTCY:221V+LS9)8Y/K6MJ>LZGKDUK/JUW/?S66GV>DVK3_ #>1
MINGPBWL[.+ "I#!"H1 !GJ22S$U\9DGC-PIE&79I3QG@?D^=9K6Q^:8C#8W&
MY3[/#XRAFF=8W&RHX["4LEE#!T\)EF(I8'#T,LG27-3A*G6P\*"C4]7'<'9K
MB\3A9T>-\;@\)3P^%A5H4,4YU*53"8'#T%*C6GCXNNZ^)I2Q%6>+C)^])2IU
MI59.'Z&ZAH'PQ-MIW@>TTKP*ITI/%7BV#PTOC. :-J=ZFJZ=X;\.WGB37S=O
M(UU#H(OM9O\ 3H+A7+(4CB)*$MMO#GP9O!_PC%IHWA,>&-7^(GB#S;Q/$L(U
M"WD\*Z%"=,L;:234()C9>(=4AU&.)S<QV;:?<QB.:.ZN(73\Z%5>ZJ3R3E!@
MD]SE1DG_ !^M3J%Q@J/0?+T (Z8' !].E>I5^DIA9UO:S\"^&Y14%@N2662G
M?**=/"T*&5QE/ABT*"H4:U&M[)4XSA5C*G&E5C5JXCSH^'%:$>5<<9DFVL1=
M5E%?7)3K5*F*:6;^_4=2I3G%U'-IP:E*<'"G1_1C0=#^"6A:WJ/C32-&\/6@
M\/:K=KJ%KK7B>T8:#)HOAL7]M>^&M+BU&[_M&XU?6Y8XH83<:@D,5O.I?S28
MU\>^%VC_  PU^RT6;Q\NG7GB'Q]XUUQ9KJXUEM/;0=+LK)[N226*">".*76=
M3G2UM6NV@BRYEA8; 1\H*%*C*@X.1\A."">>G^?QJV,$\#)/^R><>O';].W-
M?*9EX\TL7F.08F'@KPQ1RW)YYOB*V0K)J_\ 96/Q^;XO ?6<?5PM/(Z=..(A
ME>"EE^'YU7CAIXK$8G#JC[E&/J4.!IT:&.A+C/,YXK&+"0IXYXN'UK#X?!4<
M3['"QJSQ\Y3I2Q>(CBJB7L_:^PITJOM;SJR_0NV\ _!^0^-=?M?A\UU;:#:V
M]O%HBZ@EU_:TMCI-Q<ZQ=>&8;?7'5DM+M['^T;B.[U5K6%9('A2XD8BK8>%/
MA5X5U;2O$]O+X7MVMVL-<TD0>(K._"V^D^%I]3U*22U>Z>17U+6[JWL+2WN
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M>5IEJG_LM=I55GS5JTN]6J_OG)_J3A8\F&P\?Y:-)?=3BOT"BBBLSH"BBB@
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ME_\ \PA]9Q/_ $$XC_PHK_\ RXS?[(TK_H%V'_@);^W_ $S]S^7O1_9&E?\
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3"BBBD,**** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ea029753101_img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029753101_img3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "\ G # 2(  A$! Q$!_\0
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MS^*8I5A-LDNRS>61HW /W$HK\5?V6/\ @H9\9/V^/V5OVH;GX+^!/AE^S_\
MMQ?LQ_%OQ?\ LZ?$?X<_'C5M?\6? [P=\9/AMK< \3&^\2>$_P#A"_%7BSX:
MGP__ &]>13VL5A<1M&J!=EO.9?V#CU2WL].L6U>]TNTNS8?;-087:+I[-&4;
M6WC9B$>..1Y65GX#'G"K)D Z>BLZRO;74K6"^L;BWN[*Z475I=VUQOCF1EX9
M6'# @D, 2!RKHI!KQ7XN^.M8M/@?\3O'?P8U'P'XJ\4^'/ ?C#7_  G-K>HR
M:EX"U#6/#NB-=>3XBNO#,A=HCY8CECMW9D4KQ'&,Q@'O=%?DK^S!^TK^U?\
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M5"<1AW1"2P!W;@IZF@ HK\#/V@O^"I_Q=\$_$W]OW3/A!X-^#B^!/^"9NA?
MB3XN:/\ %35?&S_$7]HGQC\;]$;Q=X?^'OPA7PU*$\*W%[X:ET#PCX \9^)K
M7QZGCKXA^*#;)\/DM[:WE;]V=-NOM^FVMU-;W6F/=68NVL;TXU*P+=5<9<J8
M\\_>PQ Y#%0 ;5%03=#]!_.OR<_8G_X*;>!_VQ?VJ_VVOV:='T >'-0_9;\4
M>$8_AOKES-.\WQJ^#OB""Z\/>(/BOX<EN$AM[GPS%\5O#'B3PK%-X6$UN(G\
M(&0BXGF1 #]:J*_(+_@H;^VU^TG^R_\ 'C]B+X._!?P3\#?&<7[:?QEU7X*V
M5]\5;WQUI$W@?6M#\-MXE.O.GA=2WB'P\8P?-6)(YE+ *0LA)XWX]?\ !1;]
MH#]@+Q;\+M6_;W^#7PJ'[+7Q)\=Z+\-+S]K?]G3Q[XCU+1?@WXP\13-%X=C^
M,_P;^(OA&+Q/X>\+>+)-ZR>*O!WCOQZMML4SQ*\UL9P#]KZ*_*OXR_MQ>--7
M_:Y7]@C]D;P-X3\?_'S2?AMH'QK^.?Q$^(NK:_8?!+]FWX<Z_=36_AN7Q%%X
M/6;Q9\3OB;X[7R)OA]\(O"<_@C?9S2^/]4\?V=I;SPGH])^,O[;?PX_:6^ 7
MPB^-GPY^"GCCX4?&:\^(^FW_ .T1\&QX]\*GPAXO\,> YO%?A?P+XA^$OBD^
M.Y]$'C,:%XE,7BD?$2>W">'VBDMXILQD _3&BO@7_@HU^TU\1?V/OV-/CU^U
M%\-O#G@OQGJ_P(\!:W\2-3\*>.+O7M+TGQ)HWAZ/_2-%@U[0/^0%XAW2*D9>
M.6-G7:5QD+^>VI?\%4/VB?V<M0_8*\5_MB?!/X-CX!_M^Z_\,/AMX1^+'P#\
M=^-=6U7X._%_XQ>'$\4_#SP[\1OA[\0?"JR^(?"?B\2W=NGC'P?XX1;6?PU<
MSM83VZPB< _H#HK\N_V$_P!K'XT?M"?'G_@HE\(OB[HGPYTH_LC?M(>$OA+X
M)N_ %IX@A74/"OB3X3^&OB+'K&O2>)9KB2;7W7Q'&9)$2***4RV_V=HT62?]
M$['Q=X7U2+4)=*\2>']4M=)S'K=[INN:-J*::4B)']M^5*1;916^4N'(5\8'
M- '8T5\(>'_VZ?V=O&G[+_Q8_; \!>*AXH^"OPCL/C]J&I:[X=N]'D3Q'H_[
M.]UXJT;Q7K?AA1)(/$"SS_#S7V\%S9$5\%7S%C"1^5X;^R!\9?VX/C)<_ C]
MH/QPW[-EQ^R1^T%^S7I/QLUO1=('B?PK\7/V>/&/BK1/#OBG0?A__P )"_B[
MQQX.^*OAN/PMKDR^./%\:>!Q:>-O#LAMEALYECF /UAHK"TK6=,U_3;?5](U
M'3=3TV^0&QOK"^34=.O5;."DT0"'E2#L+$<YW8Q5:+Q'HLT4MQ!K&FSV]K8+
MJ-VRWT;!-)VLQU8E 3Y>U&)? 0@8\T-L! .FHK!AUS1;R^;3H-2TVYU0V0O1
M9VMW&VH?V:S )+L1Q,JM)@#E%R0<C[U>*?&OQ-\1;'X7ZQXP^ ND>'OB'XMT
M!XO$]AX,U2^>/3OB-INA39UGP%X>\3PHT7AWQ/XH\AHO _BB=;VP3QA';/J,
M;:?]H% 'T317SE^S3^T%\/?VI/@C\/?VA?A3J4^I> ?BEHD&N^'5U"TDTW6=
M/VW$UOKN@>)="D _X1[Q5X0\3G6_"GC>T83/;ZCH-Q&99F,3K]&T %%%% !1
M110 4444 %%%% !14/G+_G/^%5: -"BL^B@"Q15>B@"Q115>@"Q15>K% !15
M>B@#0HK/HH T**SZ* -"BJ\4H88/^?\ /^>.EB@ K^>G_@M]8:GJ/QO_ ."*
M>G:7XEO/"NH7W_!47X:66G>(;/3-#U9](U,_#[XA_P#$T2'7Q(DCQ@']VX=&
M0MM+S>3G^@ZODCXZ?L4_LO?M*>)O WC+X[?"/0/B;XF^&EX=>^'.MZ[=^(&;
MP5JP)E37/#*VWB2*/0O$RF.-E\4111S!D0^=OP* VWT]3Y*_X=K_  F\+^*?
MVKOVIOB_XW\?_M)?M#_&O]G;6O@MK_B[XDOX?TO2_!'P?T?1(_$:_"7X<>'O
MA9X6\#Q^%O"\OBV,^+IY4CF\=74YC\F^D\IO-_GY^&?PM^''[-W_  ;\?LY?
MM\^"- U72_V@?$GP&^ ?P1^.W[3.GWOCGQ5X]\-_LG?$;]J#PTWQHT:"./Q+
M'+#X2\)^%W>)(_"7DX-L#%!'&LSC^S'Q3\.O"GC;P-JGP]\3Z0^J>$-9T!O#
M^N:-+J>K,=0T=E(.DRZY%/%XF* #)D299FC)0%2Y%>3?"S]DS]F_X,?!6_\
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M,ET?"_A&/Q:T2B^7P7:^#5N4D\IXV1YH2#/R2^"OA/2/&>E_\',/AOQ-I_\
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MGWPH_P"SI\.OB \EQ':W/AF?Q7XD\4>+[?POXND-EXX^(GASP<DB3"SN0_\
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M2Z\1?\)I?:2Q"#0SK9\1R_\ %*Y!(\+OBTX4F+'WP5UW7WK_ #/PI_X*D?\
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M ()L'0;XWFL+_9S^(?CYX;T#7\*CJ%,V5B*Y8+M'DJ0%67[SUK]E#X%?'/\
MX+Z_M-> /B_\/-/^('PW\4_\$RO@1\0O%'P\\53ZUJ'@/QEXNF_:#^(WAL:[
MXF\+28\,^)&BMO#T,<(NT,*W"7#) 7-W%7ZP7W_!-O\ 8?U+X.^"/V>]0_9S
M\!W?P6^&_B=?%_@+X8M_PD"^$?"'BR'S#'K^BZ,/$2I"8WEE=8@SJAEE=5 =
ML=W;_L8?LQV_Q@U;]HF#X4:5:_&WQ%X.'P_UWXHC7/$#>,=3\#X&/!+Z\OB$
M3?V!D,HM%Q&0"!AN@%UW7WK_ #/Y+?V<?C+X@\!?L=?\$B_@Q\1/BCI'@O\
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M&E>))TE\2:%X=\._$?Q+XU\-^%?#OBL1HEU9>$K:PM9Q/)!-$\>]%[O]E?\
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MMN]FVM%9VU['](__  R[_P '&&?^4G/[(^1Z?LQZ)GWZ>$*N#]E__@XJ//\
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MB6P_T[Q5I%R!@D#30IXQ[ <]??MR37^=W9?\')O_  5<N!@_$GX*X]!\#=&
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M[]CS_GU'6O\ ./LO^#C[_@JE<#!^)'P?[CCX&Z,OKZ..IZYX]JZZQ_X.'O\
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M'%\?9%@_BE+Y+_@K^ON/]( D^GXD@9_R,GZ"I3ZEEZCN/4>WM_+WS_G4V/\
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M-_!NB7_CSX4#3/$GCWP?H5^1\&-%W#2/$OB'P_X=9@1XOR#FXF8L,$;N,!5
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MLW\,7%2NU*_+=MQ=MERO>ZMX6*RC/G@E@?[#E))MW2>MWJF[>JT=]3V_5?\
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M_6K'_#@+_@I7_P!"5\(/_#QZ1_\ ,?7UW^O7"'_0\I^MX?Y'Y/\ \0]X\O\
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MRK6RZO=:>?[!?\&S! _9N_:3R<$_M 6&/3_DG_A$DGZ?0U_G0^,O^1V\9_\
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M</V(? O[8O[,'P>\6_L^6]CX%'C[PIX(T/3M#U-?&W@_XD_M^>)/@CX>\/\
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M-MO^"Q5C>?VD/#?PR_M3&?[0'[2K?VK@9YW8VG\"3[9KL;/_ (-Q?^"MZ_\
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M_P"'?#G4^*C_ ,5$!X-R/^%@ 8R<@CZ3_P"(7_\ X*X?]$X^ O\ X??0O?\
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MEE<OAD!+@(AV*&);^6P?\&PW_!7=NGPX^ 9[_P#)=]!_^9+_ #^(K\)X?SG
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M\'_9F_8N^!7Q^^'OCSXHV_C_ .)OA[0='^)?Q+\'6%AK8\!_VO\ "71OAO\
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M7];"LOR$[F0D$@>B:3_P;Z?\%-+,X7PA\([4_P"S\;%;^7A,],_GQ747/_!
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M*VB>ZZGDXS*L?)O_ (PURU=MWI=M===^N]_DNT^*?_!)SX6_#/XY:9X)\/\
MC?XQ>(O"P^!'[8_Q?'@B]L=!/Q<^).L_LF?%_P 2_#4?#_X<X\)#P>/%7C?P
MH?\ A,@#X$Z?\)@1C(KT3XP?L,_ SQ)^Q?\  +XZ?#^V\6?!S5/#7PW^#2Z[
MKGCCPCH6D'Q)HOQL_:<^)'PV_P"$@^-)\,* WQ4\$^%?#_ATEE)4<+G<"%X"
MW_X-Y?\ @K'YUK<W_ASX:7MS9_\ (/U"\_:#E?5-.^DBH48#'\+'K[UTT/\
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M[OU?YLZ%LO1?D%%%%(84F!Z#\A2T4"LNR^Y?Y"8'H/RI:** LNR^Y?Y"  =
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MNOJ\-](3@:.CAQC=+9JFHWMHG>2]V^FWPGXZ:7'*Y&>Z]25 [>_],U[A\-_
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M>3/UEAZ#Z'^=3U!#T'T/\ZGK%[OU?YLZ%LO1?D@HHHI#"BBB@ HHHH ****
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M^WS_ .GO]F2ML/U_P/\ ])9R8G[/R_\ 2D?KI1116)U+9>B_)!1110,****
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MWP^\6$PQ>!?#'A3Q#X#\.GQ3X3\<)XH\(/%\/OM#^#O&\GCHPMXD\6HQ))H
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MH8[6C)Z@89<,",N@_G8T4H'S%D+A?O=<\9!]17V9^SSXE\;Z7XYTRT\!6O\
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M% !59NA^A_E5FJ\_W6_W?ZFFMUZK\T3/X)_X)_\ I$S\OO\ @C9!]G_X)V_
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MO/@!_P %:K;XIW7Q0TV\T.[\3ZQH_A(:_KM]\2_!<>DJ]KX'\5^&9/\ A']
M^7PBGQ._X1G6] \%J7\"CX;W'CP?\+#C\V&0!NZTC]AGX^7W[/7_  3.\#?$
M'P7JOC;XC?!'X[Z2W[2FKW_QUD\Z3X Q#XV!]"U[7SXI5OBG#&WB;X;>+V\(
M1BY5I/#RJ)$*^6?IC]IKXN_M^>#?C-=^$/@A\+TUSX>7OB'07LO'$?P<?Q]I
M>G^#M8\/^%9->#.GQ<\!2-XFC\4K\0C+$Q,31OX1CE5XI7#^$W/Q&_X*#Z_^
MT/X8\9:G\'?B!X?\+7GPH_LO_A%#X4U_4_A[X9UT?#_Q-XJ\->/_ ! ?"_Q;
M#^)?%R^*_$ \)_$#P<G@564+'\/HF"A/B$ #@?$_AC_@NI8/J.F^&_%?A&\A
MTSQW-%X?OCK'P)=]3\$_\7)70R__  D_@XLEN3'\,UEE<KXY./% 9\M!N[+Q
MMX>_X+<WOA?X</X.\;_#S2?$5OX#\'67CH2CX4F4ZU_PG?B,?$K78TD\(GPF
MOBL>#XOAL? $,:CP"&7XPM(@D/@(GJ]1^)G[?_B/Q+\)O$$GPB\?6NM^!],\
M9:R/A_INEG2/ ?CC6)OV>?%%QX=U_P"(WBR/XNKX8\QOB>?^$8'PC_X0LW'@
M'Q^?"%V9<CSCU-[\9_\ @I+<VAM-(^%WAR$WMI\.)1XHUWX7Z_L\,Z/JGBGQ
M%_PDVO\ B#X:Q^,%\5^)?$_BCPTOA:";P9X'\;J/AX_B7Q<ET6E\%N90#[$_
M9^\-?M-Z#X\^.MK\<_&C>// T_BK1C\#=>OT\#:/K2>#U6=->T/6M \*^&8D
M,D4JZ)$?%37<+>.3.;C_ (03X>M L5W]G5^,WAF3]N+Q-X4_:N\1:_X;^*7A
M7QCXD^*'P&O--\*:5-I&DOX9^'.@>(O#6@_&CP[^SQKEQXQ\<^%?$_BE/A5H
M?B1[?Q1+'X#A\:_$#Q%$(H[<VULJ8'@7PE^U[J?QK6Q\7ZC^TS+^SQXFU+Q;
M:^#M*U3Q9KGAKXA_#CX.Z;I.O^)_#GB'7_B#X7\7;O$WBKQ5XS$7@U/"?C-#
M^T!8^"F\%3GX@F0>/T< _;BBOR1L;+X]>%?V6OV=@NA_M2>(M?N?%/P9\7?%
M>^O_ (D:]JG[0?AK66\2>&T^(OAOQ#H81E\4?"__ (1B/Q&LJ+X[W*/*!C)V
MDS6'QV_;AU;XZPO;_!K7-+^!6H?$W2=.M+/6?@T\?BK3_A[_ &U\,+!_$/B'
MQ$OQ=?R) GC[XB>*5,?@1I(1\,W13N>3>GL_1_DP/U;?[S]<;$^F>,_KFOY=
MOVV+2_T+X<_MZW<%Q=6K:K_P5%^&]XK65]_9;A6_9 ^%I8"0DG#&-&89R[*I
M.2M?U$C)A)P>8E &"3PP[#/X_0^E?SE?\%)-#_LKX(_M%7/;6?\ @H9X,U _
M^(_>&/;_ .MDFOS'QKQ3H^"?B;.#<)_ZH5.649.$TW.-TI1<91>FT91?R/4X
M3PRGQOP6I)2_XRJ#:E%2]UQUNGS+ET[<NNI^1_@[5=2\BU_XG>K=O^8]KV?Z
M<^G6OK3P=?:E_P!!+5O;_3]>_'C^G./:OD'P?_R[_P"?[M?6G@G_ %-I^'^?
MQK_G9XXXCSF*FEC<6EJE?&8M)I<VCMBHZ-:.VMKG^C>54*#YOW%"7Q*SHT7?
M9):TGOM\S[%^%/Q(\5?#GQ/IOBKPWJ-T;FTP;ZQO;_&E7^D<E="U\J,(Z'YD
M=<,K8*U^ZGPA^+/AOXM>';?6M$E%K<E?+UK1;L[-4TW4\*6CD7=C=G=T!5T(
MVX(*C^>?0\D^IX]_3TK[%_9Z7XB_\+$TT?#W/]I<?V]]L+'2O[(YQ_;_ )>7
M\S^YY?S9^[7ZY]#[Z4'B)X;>(.4\!NIBN*.">):RI5>%JGM\5B*-6K-1]MPX
MYNO44HRE[2=.K)4Y*$KZZGYUXR>'G#O$7#]3B",*/#F?</TVI)J$*=:,4VHS
M<5&,E*[2;4FN=+X6XG[==*L57@_U SUVG^56*_Z%J<N>G"?*X\\(3Y7O'GA"
M?*_./-ROSBS^%FK-J][-J_>S:O\ .U_F%%%%4]GZ/\F(_.;_ (*$Z9_:1_8G
M9/\ EQ_X*!_LU:BQ]H)/%8)_[Y<5^B"?=/T/_H0KY$_:PT1=:?\ 9KQS_9'[
M5GP>U[C/2 ^)0.GJ92*^NT^Z?H?_ $(5M7_W;*_\<_E[VG],\O#+_;<U=M^7
M7O:/I^5RS11161Z:V7HOR04444#"BBB@ JN_^L;_ *YM_P"@FK%5W_UC?]<V
M_P#0336Z]5^:)G\$_P#!/_TF1^='_!*72IM%_83^#VESXWVFN?&2,_C\>_B<
MV#^!!_'%?HUV;Z)_*OC_ /88T/\ X1O]F7X?Z+S_ *%>>/U_'_A8WBT_^S^W
M-?8&#AN.R5KF7^^YFT[WD]?DOZ_X<\K)5;*,LW7N2T>ZUJ>2MZ6):***P6R]
M%^2/7"BBBF 4444 1IP"3P#CG\Q^%?FQ\8M)N;C_ (*8?L7ZX/\ CWM?V>?V
MP[!C_M'7?@/]>B[1G_&OTE;@X[#I^/)KX]^(>A+>_MD_L[:YT_L3X6?'RS[\
MG6+KX9,?U@]A^5=N"?O3D[:T*K]+4VG]]SS,RP_-A4UK:I%VO;[:>WW'V!5B
MJ]6*XWN_5_FSTH_#'_"OR04444AA1110 4444 ?(_P"W?9_;_P!C?]IVT'/V
MKX%_$L8_[EJX_/ 45].Z+_R"=-_Z\-,_] 2O'_VF=/\ [;_9X^-VECG[7\-?
M&5G_ -_/#\Y(_,FO9M,_Y!UM_P!>B?\ H K=_P"YQ\IR_P#2$<MO]M7^%K\3
M5HHHK Z@HHHH **** "J]6*@FZ'Z#^=-;KU7YHF7PR_PR_\ 29'YR_L(:5<Z
M=\1_^"ATEP?W>J?MU^,=1M?]S_A2_P #AD?1@OY5^CK?Q_\  :^/OV8=".E^
M,/VLKK!_XG'[3NNZA^?PZ^&7UZ_KFOL%OX_^ UOF7^]PM_+3OZ^RI'F9+?ZF
M[_SU/+3VDF24445SGJA1110 4444 5@,$GUQ^E?G)^UYH]WJ'[5G_!-:Y@^Y
MI/Q^^,%Y> ?W!^S!\6!P<]\YK]&6SE2!G&>V?2ODGX_^'_[8^-_['VHGIH/Q
M9\9ZB1T^]\&OB5&3^2_E^-=&6NV+J/\ NS?K:G4T/+SS#?6L(DNDH/KI:I"3
M?RY=?(^NH>@^A_G4]00]!]#_ #J>L'N_5_FSTXJT8KM&*^Z,5^@4444AA111
M0 4444 %%%% !7X\_M*?$?\ ;3\$_M,V>H?#;PIXX\6?"CP7I^F:EI'@[P]\
M,_'&J^%/&>F^(_#8A\3Z1XA\1>'_ !,89/%B>+(PWP[:6V:V\"J@:6&2)V1O
MV&HH _%G2/VHO^"B<?A;QKK'B3]G[0+>_P!'\#Z'XB\)^&O"_P $OCWXJUK4
M?&'BGXA'P_#X U]O$OBOP.DB^#/#WEI\0/%'@D^-[98)'\?0J+55LI.,\ ?M
MQ_\ !0KXQ_L\Z#\4?AQ^SS\,KSQ7XB\6ZQH(O;[P'\5QX2\,:MX;T#XECQ!X
M<_X1U?%:^,O%$0\7>&?#W@]?C$Y\!_#UG\3,>=B[/W1K/LH+6P?[!8V=K9VB
MYQ#;0)"GXJF%/7'3IQTH _$K1OVEOV_M;^(LOB*]_9Q\3/X0L(]:U'PIX,LO
MA9\6O 6L7>J:#\/?B-.Y\0^)'\8MX/U]+CQ7%X5\+3>#O&7EK<2(ES\.-\@$
MM?7OCWXS_M >&?"/PEU#P[X.OO%5]KN@^-O$/C76M$_9X^,&I/\ VUX>CC?0
M_ 47P<D\6_\ "6_#S7O&@N]: \7^,_',UE;W/A=(V)G\8PQVOZ$44 ?A=9_M
MA_\ !1/Q#I&HP:G^RUXC\.6>K6Q\(C6]%^!GQ9'BSP6TB/&/BVWAYO%H_P"$
MK3=(7C\$>"R=KB/9\10J(HP/A9\7_P!NS^R?V;8/&'PO^.NCR>#?$'C+Q+\3
M=1'@'XJ>+-:^*DOASX<_$_PJ-'\1GQ5XJ8^%O#1\1CX<^+O^$0DW#X@^.O$@
M3X:?\(#'X%8']\*L4 ?AW\(?VI/^"CGB75K5_%WP!TGP[IGB/XJ:W9"/Q9\$
M?CSX5AT+X=>'O"OAZ;P]##;^&9/'7BI?%/CCQ$/$U[)XM\6QQ_#_ ,#'PJ_@
M><22>.O TS_8?[)/CWXU?$2Z\9:A\4=%O/#=^OA_X;W^N^';^PN-)M?!WQ*E
MD\3'Q5X?\.IX@(\96^@3^$M#^'WB^+PWXN0WD<GBPOY?@U5:SE^^:$@B@!,2
M[<8Z'W'K0!%*A8<'!&>G]/?//^17X8_\%8?!NLG]F_Q ^CZ-JVL7FK_M6>#]
M?6RT:P_M25E;X?Z]X;9BG&,E4\S&-C,HP-U?N@Q^9?\ /4XJG%;0XG78,2.I
M?WY(Z=/T[FOCN.^&:7%G"&>\,5:JI4L^@Z56K9M4XR:3;BFKVT?*K)VMI<ZL
MJQLLJSW*<XA'VE3#R=2--NR;A:6]GRWMNE?IZ?Q!>#O _C:#_F2?&_\ X26O
M>G^>">GYU]5^#O"WB['_ "*7BNTZ?\P#7C_+G&??\\5_6F0BLP$4> 2.5[ _
M7Z?EGKFFA8R0#%&<X!^0=,U_ /$/[.+*LWNY>)52CSWM;A=2MS-\NJSM?"Y+
M5K[-[=#]WP7TDJV$^'A?!RY79WQ%17MO]A[VO\S^>+X3_"+Q[\0/$^F^'-(\
M.:K93W8!U"_U&PUS2=)TW1^  ">F?X1GJ<9R>?W"^%'PF\/_  D\-QZ%HB_:
M[N;G6M89P-3O]2 4O+(X! ;"OD9X49QZ>LQI&L8*1I&=Q'R#'K[FB5V3R]I*
MYQG!/))!R??@5^V_1Q^AMP7X"8S&YVL8^)N.*SDJ7%&+P\:<Z%":E>G1PTU5
M5%/X9*$D^5OWW=W^-X]\6<]\1*JRV,5DV54ESRP>&J2J*I4BXV=2HU!U+;Q4
MERQ;YN64E%QU!"N!V_/_ !J:D'0?04M?V%Z[]?7K^)^8;:=M/N"BBB@#R/XG
MZ&->/P[E_P"@1\3/!^MGZ02S*,=/[Q/05ZI236\5QY9E7=M.1]<$\_Y]:LT?
MIMY>G;Y!9=E]R"BBB@ HHHH **** "H)NA^@_G4]5Z!/9^C_ "9Y7\%]%_X1
MWX=:#H?_ #X'68C]7\0:^^?R8<>M>K.3N//3I[<"HK>"*"$PQ+M0#@#\>:E?
M[Q_#^0IO?7=VOUZ+J]S.CI"RT7-+1:=?(E7H/H/Y4M(O0?0?RI:1J%%%% !1
M110 5Y'KFAK>?%?P+KI'&B^%_&FGG_>UR;PRN?\ OJ(<5ZY4'V:'S_M&P>=C
M&_)SC&/Y4 3T57JQ0 4444 %%%% !1110!P7Q$TS^W? ?C#3>][H.L61_P"!
M(P'_ *"<]?Z5VD/[J&!3TP!GZ@X_#D?YYI@1;FUV2C<"#G'&<9QZ_2KE !11
M10 4444 %%%% !5>K%5Z!/9^C_)GEGPVT-=#U;XHS'_F-?$G5]=^@ET#PS'^
M&<'C/:O57^\?P_D*C@MX8#*(EV[VRV.YY'>I'^\?P_D*;O?7?3K?H9TO@_[>
ME^;)1T'T%+2+T'T'\J6D:A1110 4444 5Z\I\;Z"NI^+/A7J+<#0?%FL:@3[
M/X8\1*?_ *WOTQ7KB?='X_S-4I88Y/*W+G8WR^V1@_R%4KV;6EK'+B=6O/6W
A_;R9/5BJ]6*DZ5LO1?D@HHHH&%%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
